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Abstract: We present the synthesis of 
the iso-bicyclo DNA building blocks 
with the nucleobases A, C, G and T, as 
well as biophysical and biological 
properties of oligonucleotides derived 
thereof. The synthesis of the sugar part 
was achieved in 5 steps starting from a 
known intermediate of the tricyclo-
DNA synthesis. Dodecamers containing 
single iso-bicyclo thymidine 
incorporations, fully modified A- and 
T-containing sequences and fully 
modified oligonucleotides containing 
all four bases were synthesized and 
characterized. Iso-bicyclo DNA forms 
stable duplexes with natural nucleic 
acids with a pronounced preference for 
DNA over RNA as complements. The 
most stable duplexes, however, arise by 
self-pairing. Iso-bicyclo DNA forms 
preferentially B-DNA-like duplexes 
with DNA and A-like duplexes with 
complementary RNA as determined by 
CD-spectroscopy. Self-paired duplexes 
show a yet unknown structure, as 
judged from CD-spectroscopy. 
Biochemical tests revealed that iso-
bicyclo DNA is stable in fetal bovine 
serum and does not elicit RNase H 
activity. 
Keywords: oligonucleotides • 
nucleosides • bicyclo-DNA • serum 
stability • RNase H 
 
Introduction 
Oligonucleotides are a class of compounds with considerable 
therapeutic potential. Unlike small molecule drugs that typically 
target proteins, therapeutic oligonucleotides act via Watson-Crick 
hybridization to a matched sequence tract on an RNA of interest, 
modulating its biological function.[1] Originally, mRNAs of disease 
related proteins have been the target of classical antisense 
oligonucleotides that either sterically block or induce RNase H 
degradation of the mRNA in vivo.[2] The project ENCODE,[3] 
recently revealed that 80% of the human genome is transcribed into 
RNA. Of these RNAs only 2% encode for proteins while a 
considerable subset, such as micro-RNAs (miRNAs) and generally 
non-coding RNAs, is involved in gene regulation. Thus, they play a 
pivotal role in the onset of disease which greatly expands the palette 
of RNA sequences as therapeutic targets in the future. 
Basic requirements for therapeutic oligonucleotides are i) high 
affinity towards a target RNA, ii) biostability, and iii) cellular 
availability. A large number of chemical modifications on the DNA 
bases, sugar and internucleoside linkage have been reported over the 
last two decades, but only a handful of those have been used in 
extensive pre-clinical or clinical tests. Amongst those are the class 
of 2’O-alkylated RNA,[4] the morpholino phosphorodiamidates,[5] 
the peptide nucleic acids (PNA)[6] and the locked nucleic acids 
(LNA)[7]. 
In our laboratory we have been involved in the design and synthesis 
of conformationally constrained oligonucleotides over the last two 
decades. Offsprings of these efforts were the bicyclo-[8] and tricyclo-
DNA[9] molecular platform (Figure 1). Unique to both families is the 
carbocyclic 5-membered ring connecting C(5’) and C(3’) and 
thereby rigidifying the rotational freedom around the C(3’)-C(4’) 
and the C(4’)-C(5’) bonds (Figure 1, A and C). 
Besides conformational restriction this carbocyclic ring offers the 
unique advantage to change the geometry of the repeating backbone 
unit in a single strand by moving the hydroxyl groups involved in 
the internucleotidic linkages to other C-atoms within the cycle. In 
this context we became interested in exploring the properties of iso-
bicyclo-DNA (Figure 1 B) in which the the C(5’) hydroxyl group 
has been moved to C(6’). Interestingly, this iso-bicyclo-DNA shows 
the same number of bonds within the repeating backbone unit as 
DNA. In this article we report on the synthesis of the corresponding 
iso-bicyclo-DNA building blocks with all four natural bases, on 
their incorporation into oligonucleotides, their RNA and DNA 
recognition properties, as well as on their structure as determined by 
CD-spectroscopy and their biological properties (serum stability and 
RNaseH activation). 
Figure 1. A: bicyclo DNA, B: iso-bicyclo DNA, C: tricyclo DNA 
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Supporting information for this article is available on the WWW under 
http://www.chemeurj.org/ or from the author. 
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Results  
Molecular modeling of monomers: To investigate the influence of 
the C(5’) → C(6’) hydroxyl shift on the structure of the nucleosides 
a conformational search was performed using the MM+ force field 
as implemented in the software package HyperChem™. The C(3’), 
C(5’) dimethylated iso-bicylo thymidine was initially built in a 2’-
endo conformation and then energy minimized. In a conformational 
search experiment all endocyclic torsion angles were then varied, 
resulting in two different low energy conformational families 
(Figure 2). Table 1 summarizes the endocyclic torsion angles of the 
furanose unit and the corresponding energies of two representative 
structures of each family. The lowest energy conformer turned out 
to be that with the 6’ substituent in an axial position (Figure 2a). 
This structure fits well into a B-DNA double helix as judged from 
simple model building. 
 
a) b) 
Figure 2. Lowest energy conformers of 3’,5’-dimethylated iso-bicyclo-thymidine:. a) 
O(6’) in axial position, furanose in C(1’)-exo conformation;. b) O(6’) in equatorial 
position, furanose in C(4’)-exo conformation. 
Table 1. Results of the conformational search experiment for an iso-bicyclic thymidine. 
ω is the angle between the phosphate oxygen and the C6’ 
 ν0 ν1 ν2 ν3 ν4 ω Furanose 
pucker 
Energy 
[kcal/mol] 
a) -41° 35° -17° -6° 30° 82° C(1’)-exo 29.22 
b) -36° 15° 8° -30° 41° 170° C(4’)-exo 30.26 
 
Synthesis of the iso-bicyclo sugar: The 
bicyclic silyl enolethers 1a (C(1’) alpha), 1b 
(C(1’) beta) used in the synthesis of the 
tricyclo sugar[10] were considered to be the 
starting materials of choice for the synthesis 
of the iso-bicyclo DNA scaffold. 
Hydroboration of 1a or 1b yielded the 
compounds 2a, 2b and 3a, 3b (Scheme 1) in 
diastereomeric ratios of 4:1 in the -series 
and 10:1 in the -series.[11] The lowest 
abundant isomer 3b could not be isolated as a 
pure compound and was not used in further 
transformations. All other isomers 2a, 2b and 
3a were taken forward in the following 
nucleoside synthesis. Acetylation of 2a, 2b 
and 3a was performed under standard 
conditions using Ac2O/DMAP in pyridine at 
room temperature yielding 4a, 4b and 5a. 
Desilylation with HF/Et3N (37% HF) in THF 
yielded compounds 6a, 6b and 7a. To 
defunctionalize C(5’), the alcohols 6a, 6b and 
7a were converted into the thiocarbamates 8a, 
8b and 9a in good yields. The subsequent Barton McCombie 
reduction was performed with AIBN as the radical initiator and 
tris(trimethylsilyl)silane (TTMSS) as the H-donor to yield 10a, 10b 
and 11a, again in good yields (Scheme 1). 
Synthesis of the phosphoramidite building blocks: The 
nucleosidation of building block 10b (for nucleosidation of 10a see 
supporting information) with the bases T, ABz and CBz was 
performed under Vorbrüggen conditions leading to close to 1:1 
mixtures of anomers 12a/b, 13a/b and 14a/b in 75-85% yields that 
were not separable by standard chromatography techniques (Scheme 
2). Subsequent deacetylation under mild conditions yielded 15a/b, 
16a/b and 17a/b. We decided to invert the configuration at C(6‘) at 
this stage. Therefore the free nucleosides 15a/b, 16a/b and 17a/b 
were converted into the corresponding C(6’) mesylates 21a/b, 22a, 
22b and 23a/b. At this point it was possible to separate the - and -
anomers of 22 by column chromatography, while 21 and 23 had 
unfortunately still to be taken forward as mixtures of anomers. 
Subsequent acetylation of O(3’) followed by displacement of the 6’-
mesyl function by CsOAc in DMSO yielded 24a/b, 25b and 26a/b. 
Saponification (→ 27a/b, 28b, 29a/b) and subsequent tritylation 
gave compounds 30a, 30b, 31b, 32a, 32b. As already observed in 
other cases the tritylated nucleosides 30 and 32 were now separable 
by chromatography and isolated as pure isomers. The relative 
configuration at the centers C(1’) in 30b, 31b and 32b was 
ascertained by 1H-NMR-ROESY (supplementary information). The 
treatment of the beta-nucleosides 30b, 31b and 32b with CEP-Cl 
under standard conditions finally yielded the desired 
phosphoramidites 33b, 34b and 35b.  
For the synthesis of the iso-bicyclo guanosine, a slightly 
different protecting group strategy had to be employed due to the 
notoriously high degree of insolubility imparted by the guanine 
base. Thus the O(3’) and O(5’) acetyl groups in 10b were replaced 
by TBS groups, leading to 37b that was subjected to nucleosidation 
with 2-amino-6-chloropurine under classical Vorbrüggen conditions 
giving nucleosides 38a/b in an anomeric ratio of 1:1 in acceptable 
yields (Scheme 3). Treatment of 38a/b with sodium hydride and 3-
hydroxypropionitrile exchanged the C(6’)-chloro substituent by 
oxygen (→39a/b). Further protection of the exo amino function of 
the guanine base yielded amidine 40a/b. In order to invert the 
configuration at C(6’), selective desilylation at this position was 
Scheme 1. a) 1. BH3.THF, THF, -78°C→r.t., 22 h, 2. Oxone in sat. NaHCO3, r.t.,2 h, 80% b) Ac2O, DMAP, pyridine, 
r.t., 95% c) HF/Et3N, THF, r.t. 85% d) TCDI, THF, reflux, 82% e) AIBN, TTMSS, toluene, reflux, 82% 
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desirable. This goal was achieved by the use of HF/Et3N (→41a/b). 
Despite desilylation with fluoride ions is known to be unspecific[12] 
we observed high selectivity towards deprotection of the sterically 
less hindered O(6’). The free hydroxyl group in 41a/b was then 
mesylated (→42a/b), inverted (→43a/b) and the acetyl function 
removed with concomitant removal of the amidine protecting group, 
leading to the chromatographically separable anomers 44a and 44b. 
Reprotection of the N(2) amino function in the -anomer (→45b) 
and DMT protection using standard conditions yielded 46b in good 
yields. Subsequent deprotection with TBAF (→47b) followed by 
phosphitylation finally concluded the synthesis of the iso-bicyclo-G 
building block 48b. Again, the relative configuration at C(1’) was 
confirmed by 1H-NMR-ROESY on compound 47b (supplementary 
information). 
Oligonucleotide synthesis: Modified oligonucleotides were 
synthesized using standard 
phosphoramidite chemistry on a DNA 
synthesizer on the 1.3 μmol scale. Either 
natural deoxynucleoside derived CPG 
solid support or, for the fully modified 
strands, a universal solid support was 
used. For the incorporation of the iso-
bicyclo nucleoside building blocks the 
coupling time was increased to 9 min. 
All other steps remained unchanged. 
After chain assembly the 
oligonucleotides were cleaved from the 
solid support and deprotected by 
aminolysis at 70°C over night, then 
purified by reverse phase or ion 
exchange HPLC. The expected masses 
were confirmed by ESI- mass 
spectrometry.  
Biophysical properties of oligo 
nucleotides containing iso-bicyclo 
thymidines: Oligonucleotides S1-S4 
containing single and consecutive iso-
bicyclo thymidine 
modifications were 
synthesized and their pairing 
properties with 
complementary DNA and 
RNA investigated by UV-
melting curves at 260 nm. 
(Table 2, Figure S1 and S2, 
supporting information). 
Analysis of the Tm data 
revealed a stabilization of 
1°C/mod with complemen 
tary DNA. This occurs in all 
four duplexes independently 
of the position or the 
number of modifications in 
the strand. In the case of 
RNA, the iso-bc-T 
modification seems to be 
stabilizing for single 
incorporations but 
destabilizing for consecutive 
incorporations. As expected, 
the CD-spectra of S1-S4 
with complementary DNA and RNA do not deviate significantly in 
shape from that of S5, indicating minor structural perturbations 
imparted by the iso-bc-T residues (Figure S5 and S6, supporting 
information). 
Table 2. Tm values derived from UV-melting-temperature experiments at 260nm. 
Conditions: 10 mM NaH2PO4, 150 mM NaCl, pH 7.0, c = 1.2 μM strand concentration.  
 Sequence[a] Complementary DNA Complementary RNA 
S1 5’-d(GGAtGTTCTCGA)-3’ 48.0 49.0 
S2 5’-d(GGATGttCTCGA)-3’ 49.0 47.5 
S3 5’-d(GGATGTTCtCGA)-3’ 48.0 50.0 
S4 5’-d(GGAtGttCtCGA)-3’ 51.0 49.5 
S5 5’-d(GGATGTTCTCGA)-3’ 47.0 49.0 
[a] upper case letters: natural nucleotides; lower case letters: iso-bc-nucleotides 
Scheme 2. a) Thymine (2eq.), BSA (5eq.), TMSOTf (3eq.), MeCN, 0°C - rt, 85% / Benzoyl-adenine (2eq.), BSA (4eq.), TMSOTf (0.3eq.), 
MeCN, 85°C, 75% / Benzoyl-cytosine (2eq.), BSA (5eq.), TMSOTf (3eq.), 0°C – rt, 75% b) 0.2 M NaOH in 5:4:1 THF/MeOH H2O, 0°C, 75-
90% c) MsCl (1 eq.), Pyridine, 0°C →r.t., 60-70% d) Ac2O, DMAP, pyridine, r.t, 80-91% e) CsOAc, DMSO, 90°C, 81-93% f) 0.2 M NaOH 
in 5:4:1 THF/MeOH, H2O, 0°C, 60-84% g) DMT-Cl, Pyridine, r.t., 48% (30a), 40% (30b), 90% (31b), 62% (32a), 30% (32b) h) Hünig’s 
Base, CEP-Cl, MeCN, r.t., 72-87% 
Scheme 3. a) 2-amino-6-chloropurine, BSA, TMSOTf, MeCN, 60°C, 5 h, 64% b) NaH, 3-hydroxypropionitrile, THF, 0°C-r.t. 3h c) 
N,N-DMF-dimethylacetal, DMF, 55°C, 3 h, 71% over two steps d) HF/Et3N, THF, r.t., 55% e) MsCl, pyridine, r.t., 92% c) CsOAc, 
DMSO, 85°C, 16 h, 85% f) 1 M KOH in 5/3 MeOH/H2O, 60°C, 42% (53b), 20% (53a) g) N,N- DMF-dimethylacetal, DMF, 55°C, 3 
h, 64%h) DMT-Cl, pyridine, r.t., 16 h, 94%i) TBAF, THF, r.t., 5h, 70% j) Hünig’s base, Cep-Cl, MeCN, r.t., 1h, 88%  
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Synthesis and properties of fully modified oligonucleotides 
containing iso-bc-T and iso-bc-A: As for the synthesis with single 
iso-bc-T incorporations, a non-self-complementary sequence motif 
was chosen. S6 and S7 (Table 3) are complementary and can 
therefore give insight into the self-pairing of iso-bicyclo DNA. The 
melting curves of S6 and S7 with complementary DNA and RNA 
partially confirm the results obtained with the thymidine modified 
oligonucleotides. All duplex melting curves reflect cooperative and 
reversible melting (Figure 3). The iso-bc modifications stabilize 
duplexes with DNA, but not as predicted from single incorporations 
with 1°C per modification. The overall stabilization is +2°C (S6) 
and +3°C (S7) per duplex, respectively (Table 3).  
Table 3. Tm values derived from UV-melting-temperature experiments at 260nm. 
Conditions: 10 mM NaH2PO4, 150 mM NaCl, pH 7.0, c = 1.2 μM strand concentration. 
[a] not measured 
In the case of RNA as complement duplex destabilization with a 
Tm value below 10°C is observed. This was predicted from the 
earlier experiments where we have shown that single incorporations 
stabilize the duplex and consecutive modifications destabilize it. 
Thermal denaturation experiments were also performed for the fully 
modified duplex S6:S7. The Tm in this case is remarkably high with 
a value of 41.9 °C which is almost twice as high as that for the 
natural DNA duplex. Furthermore, to check the specificity for the 
antiparallel orientation in the duplex, melting temperatures for the 
parallel duplexes with DNA were measured (Figure S3, supporting 
information). Both, S6 and S7, showed Tm values that are 
comparable to the ones measured for the antiparallel duplexes (-3°C 
for S6 and +2°C for S7, Table 3). The same is true for the natural 
duplex, which was slightly destabilized by -3°C compared to the 
antiparallel duplex. 
It thus appears that, much like natural DNA,[13] also iso-bc-AT 
sequences have the potential to form parallel reverse Watson-Crick 
duplexes. It also becomes clear that iso-bc-AT-oligonucleotides do 
not have a considerable stabilizing effect on duplexes with DNA but 
have a significant destabilizing effect on duplexes with RNA as 
complement. In contrary, the fully unnatural duplex is significantly 
more stable compared to pure DNA or hybrid (iso-bicyclo-
DNA/DNA) duplexes. This is not uncommon for sugar-modified 
oligonucleotide analogues, such as HNA[14] or tc-DNA, and reflects 
most likely a more perfect geometric match of the repeating 
backbone units in homo-backbone duplexes as compared to hetero-
backbone duplexes. 
In order to get insight into the structural properties of these AT 
duplexes, circular dichroism (CD) spectra were measured. The CD 
spectra for the natural duplex S8:S9 as well as for the hybrid duplex 
S6:S9 (Figures S7 and S8, supplementary information) showed a B-
like conformation and, in the case of the fully modified duplex 
S6:S7 the CD spectrum showed a signature that is significantly 
different from A-, B, or Z-DNA (Figure 4). The CD traces of the 
single strands (at high temperature) are similar to the unmodified 
ones and the hybrid duplexes. In the paired state, however, the CD 
shows an intense negative band between 290 and 260 nm, which 
mirrors the band of the unmodified duplex in this part of the 
spectrum (Figure 4). For the parallel duplexes in all three cases a B-
type conformation is observed (Figure S9, supplementary 
information). 
Reported CD spectra of natural, parallel AT-duplexes were found to 
be sequence specific: A parallel duplex with alternating AT base 
pairs shows a negative band at 290 nm[15] whereas a d(A)10.d(T)10 
hairpin shows a spectrum close to the one obtained in our case[13]. 
However, the negative band between 260 and 290 nm in the S6:S7 
duplex is most likely not the result of a partial parallel iso-bc-AT 
duplex structure since achieving a melting temperature of 41.9°C 
with a minimum of 6 mismatches in a dodecamer seems very 
unlikely. Hence we hypothesize that there exists a different, yet 
undetermined duplex conformation for pure iso-bc-AT duplexes. 
Thermodynamics of duplex formation: Using standard curve 
fitting procedures to experimental melting curves[16] we calculated 
the thermodynamic data of duplex formation of the fully modified 
duplex S6:S7 as well as the hybrid duplex S6:S9 and compared the 
data to that of the natural duplex S8:S9 (Table 4). From there it 
appears that the natural duplex S8:S9 is enthalpically favored over 
the fully modified duplex. The free energy G25°C is, as expected 
from the Tm-data, in favor of the fully modified duplex S6:S7. Thus 
the fully modified duplex is entropically favored which is in 
agreement with its reduced conformational flexibility. The hybrid 
duplex shows a somewhat unusually high enthalpy H, which is 
 Sequence Tm vs DNA 
antiparallel 
Tm vs RNA 
antiparallel 
Tm vs DNA 
parallel 
S6 6’-d(ataatttaataa)-3’ 25.1  <10 21.9  
S7 6’-d(ttattaaattat)-3 25.9  <10 28.1  
S8 5’-d( ATAATTTAATAA)-3‘ 23.2 n.m.[a] 19.8 
S9 5’-d(TTATTAAATTAT)-3’ 23.2 11.2 n.m.[a] 
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Figure 4. CD spectrum of the duplex S6:S7 at different temperatures. Conditions: 10 
mM NaH2PO4, 150 mM NaCl, pH 7, c = 1.2 µM strand concentration. 
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Figure 3. UV -melting curves (260 nm) of the AT-duplexes. Conditions: 10 mM 
NaH2PO4, 150 mM NaCl, pH 7.0, c= 1.2 μM strand concentration. ■ S6:RNA,                     
▲ S7:RNA, ▼ S6:S7, ○ DNA:RNA, + DNA:DNA, * S6:DNA, S7:DNA 
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counterbalanced by the entropy term, indicating enthalpy/entropy 
compensation to be operative. 
Table 4. Thermodynamic data of duplex formation from curve fitting to the 
experimental melting curve. Conditions: 10 mM 10 mM NaH2PO4, 150 mM NaCl, pH 
7.0, c= 1.2 μM strand concentration 
Duplex H (kcal∙mol-1) S cal∙mol-1∙K-1) G25°C (kcal∙mol-1) 
S6:S7 -73.0 -202.8 -12.6 
S6:S9 -84.7 -254.0 -8.9 
S8:S9 -76.6 -228.9 -8.3 
 
We also investigated the influence of salt concentration on duplex 
stability by varying the NaCl concentration of the buffer in a range 
from 0.05 M ‒ 1.5 M. The uptake of sodium ions upon duplex 
formation helps to stabilize the duplex by reducing the repulsion 
between the phosphate groups. Since the negative charge density is 
higher in a duplex than in single strands, counter ions are screened 
upon duplex formation. As expected, an increase of the Tm values 
with increasing NaCl concentration was observed (Figure 5). The 
duplexes S8:S9 and S6:S9 both doubled their Tm values within the 
30-fold increase of salt concentration. The fully modified duplex 
S6:S7 increased its Tm by 35°C, which is slightly more than twice 
the starting value at 0.05 M NaCl. We further determined the 
relative counter ion uptake Δn (Table 5) according to classical 
polyelectrolyte theory,[17] using the transition enthalpy (H) data 
from Table 4.  
 
n = -2H/RTm
2 
*δTm/δ(ln[NaCl]) 
Table 5. Calculated counter ion uptake. Conditions: 10 mM NaH2PO4, 200 mM NaCl, 
pH 7 
 S8:S9 S6:S9 S6:S7 
Δn 1.1 1.6 2.1 
δTm/δ(ln[NaCl]) 5.3 7.2 11.8 
 
The fully modified iso-bc system S6:S7 screens about twice as 
much counter ions upon duplex formation than the corresponding 
unmodified duplex and about a third more than the hybrid duplex. 
This is in agreement with a higher degree of spatial compression of 
the phosphate groups upon transition from single strands to duplex. 
Whether this is due to a more compressed duplex structure or a more 
relaxed single strand structure remains unknown at this point. 
Synthesis and properties of oligonucleotides containing all 
four iso-bc-nucleosides: Two fully modified sequences containing 
iso-bc-A, -T, -G, and -C residues were synthesized: A dodecamer 
(S10) for the investigation of the pairing properties with 
complementary DNA and RNA and a self-complementary hexamer 
(S11) to get further insight into the structure of fully modified 
duplexes (Table 6). Thermal melting of S10 with complementary 
DNA shows, as all modified DNA sequences, a cooperative and 
reversible melting behavior (Figure 6). Again, a stabilization of the 
duplex was observed but, even including the more stable CG base 
pairs, the difference in melting temperature is small (+4°C / duplex) 
and comparable to the one observed in the AT-series (Table 6). In 
addition, the melting behavior of S10 with a parallel DNA 
complement was investigated. No cooperative transition was 
observed revealing that iso-bc-DNA, as DNA, strongly prefers 
antiparallel Watson-Crick pairing in sequences containing all four 
base-pairs. For the hexamer S11 a very stable duplex was found 
with for GC base-pairs usually low hyperchromicities at 260 nm 
(Figure 6). This again confirms that fully modified iso-bc-duplexes 
are very stable, irrespective of the base composition. 
Table 6. Tm data for fully modified iso-bc-oligonucleotides containing all four bases. 
Conditions: 10 mM NaH2PO4, 150 mM NaCl, pH 7.0, strand concentration for all 
dodecamers: c=1.2 μM. Total strand concentration for the natural hexamers: 2.4 μM and 
for S11: 4.8 μM  
 [a] n.d.: not detected [b] self-complementary duplex: Tm data refer to the resp. 
backbone type. 
CD spectra of the hybrid duplex (S10:DNA, Figure 7) revealed a 
completely different curve shape compared to the unmodified 
duplex (Figure S13, supplementary information), indicating 
substantial deviation from classical A or B-type structures. In 
contrast, in the case of the RNA complement, a typical A-form is 
observed with comparable spectra for the unmodified and the 
modified duplex. The CD signature of the S11:S11 duplex, 
however, shows an intense negative cotton effect at 290 nm and a 
positive cotton effect at 260 nm (Figure 7). It thus deviates 
significantly from that of the self-complementary RNA hexamer (A-
 Sequence DNA 
antiparallel 
RNA 
antiparallel 
iso-bc 
duplex 
S10 6’–d(cctactagagct)-3’ 51.0 (+4) 30.0 (-11.5) -- 
S11 6’–d(cctagg)-3’[b] <10 34.5 40.7 
0 10 20 30 40 50 60 70 80 90
0
5
10
15
20
H
y
p
e
rc
h
ro
m
ic
it
y
 /
 %
Temperature / °C
Figure 6. UV melting curves (260 nm) for the modified sequence S7 with DNA (left) 
and RNA (right). Conditions: 10 mM NaH2PO4, 150 mM NaCl, pH 7.0, c= 1.2 μM 
strand concentration. ■ S11, ○ RNA hexamer, ▲ S10:DNA, ▼ DNA:DNA, * 
S10:RNA, + DNA:RNA 
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Figure 5. Plot of the Tm vs ln[NaCl]; 10 mM NaH2PO4, 50 mM-1.5 M NaCl, PH = 7.0, 
c= 1.2 μM strand concentration. ▼ DNA:DNA, ■ S6:S7, ● S6:DNA 
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type conformation, data not shown) and also to some extent from the 
fully modified iso-bc-AT duplex S6:S7 (Figure 3). It thus shows 
some similarities to that of Z-DNA[18] which, given the high GC 
content, could be a possible structure for S11. However, more high 
resolution structural work is needed to get a reliable picture of the 
3D structure.  
Mismatch discrimination: To test the base-pairing selectivity of 
the iso-bc-DNA system, the melting temperatures of different 
mismatched duplexes complementary to S10 were measured. A 
thymidine residue in the complementary DNA sequence was 
replaced by an A, C or G and the corresponding Tm values were 
determined (Table 7). 
Table 7. Mismatch discrimination. In parentheses are the ΔTm values relative to the 
matched duplex. Conditions: 10 mM NaH2PO4, 150 mM NaCl, pH 7.0, c = 1.2 μM 
strand concentration. 
duplex X = A X = G X = C X = T 
(match) 
6’–d(cctactagagct)-3’ (S10) 
5’–d(ACGXCTTGTAGG)-3’ 
37 (-14) 43 (-8) 33 (-18) 51 
5’–d(CCTACAAGAGCT)-3’ 
5’–d(ACGXCTTGTAGG)-3’ 
34 (-13) 39 (-8) 30 (-17) 47 
 
In all cases thermal destabilizations in the mismatched duplexes 
were observed. The A-C mismatch was the strongest discriminating 
followed by the A-A and the A-G mismatches. The decrease is 
generally of about the same extent as in DNA, indicating an equal 
selectivity of the two Watson-Crick pairing systems. 
Serum stability: The serum stability of S10 was measured in 
heat deactivated fetal bovine serum (FBS) in which the predominant 
nucleases are the 3’-exophosphodiesterases.[19] As a control the 
stability of the corresponding natural DNA complement was tested, 
too. After incubation at 37°C in medium containing 10% FBS, 
aliquots were taken in regular intervals and after ethanol 
preciptiation analysed by PAGE. The gel was visualized with stains-
all solution (Figure 8). 
The resulting gel shows that S10 is stable over a period of at least 
21h without signs of degradation. In contrast, the DNA complement 
is substantially hydrolyzed after this period of time, indicating a 
significantly higher degree of biostability of iso-bc-DNA.  
RNase H activity: Due to its ability to cleave DNA/RNA 
heteroduplexes, it is desirable for chemically modified 
oligonucleotides designed to ablate an RNA of interest, to be able to 
activate the endogenous enzyme RNase H. This is, however, 
difficult to achieve since only a small number of DNA analogues is 
known to be compatible with RNase H activity.[20] To investigate 
this, the RNA complement of S10 was 5’-labeled with [γ-32P]-ATP 
and T4 polynucleotide kinase (T4 PNK) and annealed to S10. The 
natural RNA/RNA and the hybrid DNA/RNA duplexes served as 
negative and positive control. As expected, the RNA/RNA duplex 
did not show any RNase H mediated degradation, while the 
DNA/RNA hybrid turned out to be a good substrate. The S10/RNA 
duplex showed no signs of RNA cleavage after treatment with 
RNaseH, clearly showing that iso-bc-DNA does not elicit RNaseH 
activity (Figure 9). 
Discussion 
We synthesized all four iso-bicyclo nucleosides and incorporated 
them successfully into DNA. Single iso-bicyclo T incorporations in 
natural DNA showed stable duplexes with complementary DNA and 
RNA. Consecutive incorporations destabilize the RNA hybrid. The 
same result was obtained for the fully modified AT duplexes where 
a stabilized duplex with DNA and a significantly destabilized 
duplex with complementary RNA was found. An interesting finding 
in the AT series was the very stable self-duplex with a Tm of 41.9°C. 
The CD spectrum of this fully modified iso-bicyclo duplex (Figure 
3) revealed a structure different from A- or B-form duplex. 
It is known that the duplex conformation as revealed by CD-
spectroscopy is dependent on the base sequence and on the salt 
concentration of the buffer. Increasing the salt concentration 
typically leads to a decrease of the long wavelength band between 
290 and 260 nm corresponding to variants of B-DNA structures 
differing in the number of base pairs per helix turn.[21] Vorlíčková 
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Figure 7. CD spectra of S11:S11, S10:DNA and S10:RNA. Conditions: 10 mM 
NaH2PO4, 150 mM NaCl, pH 7, c = 1.2 µM strand concentration. 
Figure 8. PAGE analysis of the serum stability of DNA (left) and iso-bicyclo DNA 
(right). 1: 0 h, 2: 0.5 h, 3: 2 h, 4: 6.5 h, 5: 21 h 
Figure 9 PAGE analysis of the RNase H acitvity of the duplexes: RNA:32P-RNA 
(C12:32P-C9), iso-bicyclo-DNA:32P-RNA (S7:32P-C9), DNA:32P-RNA (C8:32P-C9). 
1: 5 min., 2: 45 min., 3: 120 min., 4: 300 min. 
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and Kypr investigated the conformational changes of poly(A-T) 
sequences at different CsF concentrations and found that the long 
wavelength part of the CD spectra falls off, inverts and becomes 
negative at high salt concentrations.[22] They called that structure X-
DNA and suggested that this X-DNA is a right handed anti-parallel 
double helix with Hoogsteen base-pairs that were found by Abrescia 
et al. some years ago.[21, 23] In this Hoogsteen DNA[23] the overall 
helical parameters are similar to that of B-DNA with the adenines in 
syn-conformation. Therefore one hypothesis is that the fully 
modified iso-bicyclo-AT duplex S6:S7 forms such an X-DNA 
structure. 
Further evidence for such a X-DNA structure comes from CD-
experiments with S6:S7 as well as the hybrid DNA duplexes of S6 
at different salt concentrations. While no major changes occur in the 
case of the unmodified duplex S8:S9 and the hybrid duplex S6:S9 
(Figures S7 and S8, supplementary information), the CD of the fully 
modified duplex S6:S7 shows a high dependence on the sodium 
chloride concentration (Figure S10, supplementary information). 
The negative band at 275 nm increases in intensity upon increasing 
the NaCl concentration. This could indeed be an indication of a 
partial structural transition from the more compact X- towards a B-
type conformation when changing from high to low electrolyte 
concentration, which supports the preference of an X-type 
conformation of iso-bc-DNA duplexes at physiological salt 
concentration. 
The fully modified iso-bc-AT oligonucleotides form also stable 
parallel duplexes. Parallel duplex formation in poly(dAT) sequences 
is well known and investigated.[15, 24] They require reversed Watson-
Crick base-pairs and their thermal stability is highly sequence 
dependent. This explains the variability in the Tms for the two 
duplexes S6 and S7 with parallel complements. However, no 
melting transition was found for the fully modified S10, containing 
all four bases, with a parallel DNA complement, revealing that iso-
bc-DNA prefers strictly antiparallel pairing in sequences containing 
also G-C base-pairs. These preferences are identical to that of 
natural DNA where parallel reversed Watson Crick is also restricted 
to AT sequences. 
Iso-bc-DNA was found to be unable to activate RNase H in iso-
bc-DNA/RNA hybrids. RNase H is known to preferably bind to A-
form rather than B-form duplexes. Hence, as a consequence the 
enzyme binds RNA/RNA duplexes and DNA/RNA hybrids much 
tighter than a DNA/DNA duplex.[25] The RNA in dsRNA duplexes 
is not cleaved since the 2’-OH groups affect the hydration pattern in 
the minor groove.[26] Since the CD spectrum of the iso-bicyclo 
DNA/RNA duplex shows an A-like structure and is very similar to 
that of the DNA/RNA duplex, an activation of RNase H could have 
been expected. However, it has also been shown that the enzyme is 
very sensitive to structural changes within the minor groove. This is 
the reason why all 2’ modified oligonucleotides (e.g. 2’-OMe[27]) as 
well as the sterically constrained (e.g. LNA[28]; tcDNA[9a]) do not 
activate RNase H.[26] From this point of view it is not surprising that 
iso-bc-DNA is unable to do so. 
Conclusions 
We have achieved the synthesis of all four iso-bc-DNA building 
blocks starting from the silyl enolethers 1a or 1b. These 
phosphoramidites were successfully incorporated into natural 
deoxyoligonucleotides or were used for the synthesis of fully 
modified iso-bc-DNA by standard solid phase DNA synthesis. 
Oligodeoxynucleotides containing single incorporations as well as 
fully modified iso-bc-DNA show stable duplexes with DNA 
complements with a slightly enhanced stability (ca. 0.3 °C/mod). 
RNA is discriminated as complement in all the investigated 
duplexes by ca 1°C/mod. All hybrid duplexes show B-conformation 
with DNA and A-conformation with RNA as judged from CD-
experiments. Base mismatches are discriminated in the same way as 
in natural DNA. Fully modified iso-bicyclo oligonucleotides form 
very stable duplexes within their own backbone series that are of 
higher thermodynamic stability than the corresponding natural 
duplexes. Fully modified duplexes containing only AT base-pairs 
show a CD-signature that is significantly different from that of the 
canonical DNA conformations. Based on the available biophysical 
data we propose a double helical structure with Hoogsteen base-
pairs. Furthermore, iso-bc-DNA is stable in bovine serum and does 
not activate RNase H.  
Thus it appears that the phosphate shift from C(5’) to C(6’) in 
the bicyclic system is well tolerated in duplexes with DNA and less 
well in duplexes with RNA. Pure iso-bc-DNA duplexes, however, 
display considerable structural differences of a yet unknown type. 
The feature of iso-bc-DNA to stablize DNA duplexes and 
discriminate RNA is interesting and could find possible applications 
in diagnostics, as e.g. in primers for PCR. 
Experimental Section 
General: All reactions were performed under Ar and in dried glassware. Anhydrous 
solvents for reactions were obtained by filtration through activated alumina or by 
storage over molecular sieves (4 Å). Column chromatography (CC) was performed on 
silica gel with an average particle size of 40 μm. All solvents for column 
chromatography were of technical grade and distilled prior to use. Thin-layer 
chromatography was performed on silica gel plates. Visualization was achieved either 
under UV light or by dipping in staining solution [CerIV-sulfate (10.5 g), 
phosphormolybdenic acid (21 g), conc. H2SO4 (60 ml), H2O (900 ml) or p-anisaldehyde 
(10 ml), conc. H2SO4 (10 ml), glacial acetic acid (2 ml), ethanol (180 ml)] followed by 
heating with a heat gun. NMR spectra were recorded at 300 or 400 MHz field width 
(1H) in either CDCl3 or CD3OD. δ in ppm relative to residual undeuterated solvent 
CHCl3: 7.26 ppm (
1H) and 77.16 ppm (13C); CHD2OD: 3.31 ppm (
1H) and 49.0 ppm 
(13C), J in Hz. Signal assignments are based on DEPT and on 1H−1H and 1H−13C 
correlation experiments (COSY/HMSC). High-resolution mass spectra were recorded 
on an Applied Biosystems Sciex QSTAR Pulsar. 
(3R, 5S, 8R, 7S)-8-((tert-butyldimethylsilyl)oxy)-3-methoxyhexahydro-2H-
cyclopenta[b]furan-3a,6-diyl diacetate 4b A solution of 2b (4.3g, 14.2 mmol) in 
pyridine (35 ml) was cooled to 0°C and DMAP (171 mg, 1.4 mmol) and Ac2O (4.0 ml, 
42.7 mmol) were added. The mixture was stirred for 16 h at r.t. and, after cooling to 
0°C, carefully quenched and washed with sat. NaHCO3. The aqueous layers were 
extracted with DCM. The combined organic layers were dried over MgSO4 and 
evaporated. FC (ethyl acetate/hexane 1:3) yielded 4b (4.9 g, 12.6 mmol, 90%) as a 
white solid. Rf: 0.9 (hexane/ethyl acetate 1:1), HR-MS (NSI
+, MeCN) for C18H32O7Si. 
calc: 411.1813, found: 411.1810 (M + Na+), 1H NMR (400 MHz, CDCl3) δ 5.24 (m, 
1H), 5.06 (d, 1H, J = 5.3), 4.36 (d, 1H, J = 6.4), 4.20 (dd, 1H, J = 8.6, 6.4), 3.36 (s, 3H), 
2.86 (dd, 1H, J = 13.9, 7.6), 2.55 (d, 1H, J = 13.8), 2.36 (ddd, 1H, J = 13.8, 5.7, 1.8), 
2.02 (s, 6H), 1.76 (ddd, 1H, J = 13.8, 9.7, 1.6), 0.90 (s, 9H), 0.11 (s, 3H), 0.08 (s, 
3H).13C NMR (101 MHz, CDCl3) δ 170.55, 170.17, 105.42, 89.29, 85.33, 77.97, 75.80, 
54.62, 47.69, 40.15, 25.89, 21.62, 21.16, -4.60, -4.71. 
(3R, 5S, 8R, 7S)-8-hydroxy-3-methoxyhexahydro-2H-cyclopenta[b]furan-3a,6-diyl 
diacetate 6b A solution of 4b (10.4 g, 26.8 mmol) in THF (80 ml) was cooled to 0°C. 
HF/Et3N (37% HF, 23 ml, 53.6 mmol) was added and the solution was allowed to warm 
to r.t. The reaction mixture was stirred for 60 h at r.t. and subsequently quenched with 
silica. The solvent was evaporated and the crude mixture purified by FC (ethyl 
acetate/hexane 1:1). 6b (5.9 g, 21.5 mmol, 80%) was obtained as a colourless oil. Rf 0.4 
(ethyl acetate/hexane 1:1), HR-MS (NSI+, MeCN/H2O, 1% HF) for C12H18O7. calc: 
279.09447, found: 297.09538 (M + Na+), 1H-NMR (300 MHz, CDCl3): 5.10-5.13 (m, 
2H), 4.53 (d, J = 6.4, 1H), 4.10 (m, 1H), 3.39 (s, 3H); 2.78-2.80 (m, 2H), 2.48 (m, 2H), 
2.03 (s, 3H); 2.00 (s, 3H), 1.95-1.86 (m, 1H), 13C NMR (75 MHz, CDCl3) δ 171.06, 
170.09, 106.93, 89.23, 85.93, 78.71, 74.79, 55.79, 47.14, 39.93, 21.51, 21.14. 
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(3R, 5S, 8R, 7S)-8-((1H-imidazole-1-carbonthioyl)oxy)-3-methyoxyhexahydro-2H-
cyclopenta[b]furan-3a,6-diyl diacetate 8b To a solution of 6b (3.2 g, 11.7 mmol) in 
THF (60 ml) was added TCDI (4.2 g, 23.3 mmol). The yellow solution was refluxed at 
75°C for 3h. The THF was then evaporated and the crude mixture was purified by FC 
(ethyl acetate/hexane 1:1) to yield 8b (4.2g, 10.9 mmol, 93%) as a yellow foam. Rf 0.40 
(ethyl acetate/hexane 1:1), HR-MS (NSI+, EtOAc) for C16H20N2O7S. calc: 385.1064, 
found: 385.1051 (M + H+), 1H NMR (400 MHz, CDCl3) δ 8.39 (m, 1H) 7.67 (m, 1H), 
7.04 (m, 1H) 5.92-5.85 (m, 1H) 5.70-5.67 (m, 1H), 5.08, 5.06 (2m, 2H) 3.34 (s, 3H), 
2.94 (dd, 1H, J = 13.9, 8.1), 2.58 (d, 1H, J = 14.0), 2.49 (ddd, 1H, J = 14.1, 5.7, 1.8), 
2.14-2.10 (m, 1H) 2.08, 2.05 (2s, 6H).13C NMR (101 MHz, CDCl3) δ 183.54, 170.40, 
170.29, 137.40, 131.24, 118.26, 106.14, 89.25, 84.34, 82.33, 73.85, 55.33, 47.82, 39.38, 
21.55, 21.15  
(3R, 5S, 7S)-3-methoxyhexahydro-2H-cyclopenta[b]furan-3a,6-diyl diacetate 10b The 
sugar 8b (4.2 g, 10.9 mmol), AIBN (270 mg, 2.2 mmol) and TTMSS (6.7 ml, 22 mmol) 
were dissolved in toluene (87 ml) and stirred for 2 h at 85°C. The toluene was then 
evaporated and the crude mixture purified by FC (ethyl acetate/hexane 1:3). Compound 
10b (2.6 g, 10.1 mmol, 92%) was obtained as a colourless oil. Rf 0.6 (ethyl 
acetate/hexane 1:1), HR-MS (NSI+, MeOH) for C12H18O6. calc: 281.0996, found: 
281.1002 (M + Na+), 1H NMR (300 MHz, CDCl3) δ 5.39-5.31 (p, 1H, J = 6.3), 5.04 (dd, 
1H, J = 5.6, 0.7), 4.71 (dd, 1H, J = 7.0, 3.5) 3.33 (s, 3H), 2.78-2.71 (dd, 1H, J = 14.6, 
6.2), 2.60 (d, 1H, J = 14.0), 2.33 (ddd, 1H, J = 14.2, 5.7, 0.8) , 2.29-2.07 (m, 3H) 2.02, 
2.00 (2s, 6H).13C NMR (75 MHz, CDCl3) δ 170.58, 170.37, 106.61, 92.63, 87.86, 
75.03, 54.99, 46.55, 44.15, 39.02, 21.65, 21.28. 
(3’S, 6’S (6’R))-1-(3’, 6’-Di-O-acetyl-2’-deoxy-3‘,5‘-ethano-α- and -β-D-ribofuranosyl] 
thymine 12a/b Thymine (293 mg, 2.3 mmol) was suspended in MeCN (12 ml) and BSA 
(1.4 ml, 5.8 mmol) was added. The suspension was stirred until the solution became 
clear. The solution was then cooled to 0°C and 10b (300 mg, 1.2 mmol, dissolved in 6 
ml MeCN) and TMSOTf (0.63 ml, 3.5 mmol) were added. After 1 h at 0°C the mixture 
was allowed to warm to r.t. and the stirring was continued for another 16 h. It was then 
diluted with ethyl acetate and washed with sat. NaHCO3. Purification by FC (ethyl 
acetate/hexane 4:1) yielded the desired nucleoside 12a/b (355 mg, 1.0 mmol, 87%) in a 
anomeric ratio of approx. α/β 1:1 as a white foam. Rf 0.49 (ethyl acetate/hexane 4:1), 
HR-MS (NSI+, MeCN) for C16H20N2O7. Calc. 375.1163, found 375.1145 (M + Na
+), 1H 
NMR (400 MHz, CDCl3) δ 8.29 (m, 2H), 7.27 (s, 1H), 7.11 (s, 1H), 6.12 (m, 2H), 5.23 
(m, 2H), 4.93 (dd, 1H, J = 6.4, 3.1), 4.56 (d, 1H, J = 5.6), 2.86 (m, 2H), 2.79 (ddd, 1H, J 
= 13.8, 6.3, 1.3), 2.66 (m, 1H), 2.54 (m, 1H), 2.36 (m, 1H), 2.25 (m, 2H), 2.16 (m, 1H), 
2.10 (m, 2H), 2.08 (s, 3H), 2.06 (s, 3H), 2.04 (2s, 6H), 2.00 (m, 1H)1.96 (m, 3H), 1.95 
(m, 3H). 13C NMR (75 MHz, CDCl3) δ 170.69, 170.49, 170.35, 170.15, 163.73, 163.44, 
150.30, 150.28, 135.31, 134.44, 112.04, 111.11, 91.21, 90.17, 87.69, 86.78, 85.33, 
83.74, 73.65, 73.23, 44.46, 44.35, 43.64, 43.37, 37.84, 36.47, 21.73, 21.63, 21.19, 
21.16, 12.86, -1.73. 
(3’S, 6’S)-N6-Benzoyl-9-(3’, 6’-Di-O-acetyl-2’-deoxy-3‘,5‘-ethano-α- and -β-D-
ribofuranosyl] adenine 13a/b To a suspension of N6-benzoyl-adenine (926 mg, 3.9 
mmol) in MeCN (15 ml) was added BSA (1.9 ml, 7.6 mmol). The mixture was stirred at 
r.t. until the solution was clear. 10b (500 mg, 1.9 mmol, solved in 4 ml MeCN) and 
TMSOTf (0.1 ml, 0.6 mmol) were added and the solution was stirred for 2 h at 85°C. 
After cooling to r.t. the mixture was quenched with sat. NaHCO3 and extracted with 
ethyl acetate. The combined organic layers were dried over MgSO4 and evaporated. FC 
(3% methanol in DCM) yielded 13a/b (654 mg, 1.4 mmol, 74%) in an anomeric ration 
of ~1:1 as a white foam. Rf 0.65 (10% methanol in DCM), HR-MS (NSI
+, MeOH) for 
C23H23N5O6. calc: 466.1721, found: 466.1724 (M + H
+), 1H NMR (300 MHz, CDCl3) δ 
8.81, 8.79 (2s, 2H) 8.24, 8.15, (2s, 2H) 8.03 (m, 4H), 7.64-7.59 (m, 2H), 7.55-7.50 (m, 
4H), 6.45 (dd, 1H, J = 6.9, 2.7), 6.34 (dd, 1H, J = 8.4, 6.4), 5.55-5.46 (m, 1H, H-C(6’), 
β), 5.31-5.21 (m, 1H), 4.89 (dd, 1H J = 6.1, 1.0), 4.73 (dd, 1H, J = 6.5, 1.7), 3.44 (dd, 
1H, J = 15.4, 2.7), 3.03-2.90 (m, 4H), 2.88-2.81 (m, 1H) 2.45-2.36 (m, 2H), 2.22-2.12 
(m, 4H), 2.12 (s, 3H), 2.06, 2.05 (2s, 6H), 1.95 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
170.60, 170.55, 170.47, 170.21, 164.72, 153.09, 152.97, 149.89, 149.72, 141.43, 
141.25, 133.85, 133.07, 133.03, 129.13, 128.07, 123.67, 91.03, 90.99, 87.65, 86.25, 
85.85, 84.84, 77.55, 77.23, 76.91, 73.46, 73.26, 44.25, 44.17, 43.77, 37.02, 36.88, 
21.81, 21.52, 21.23, 21.18. 
(3’S, 6’S)-N6-Benzoyl-1-(3’, 6’-Di-O-acetyl-2’-deoxy-3‘,5‘-ethano-α- and -β-D-
ribofuranosyl) cytosine 14a/b N-Benzoylcytosine (833 mg, 3.9 mmol) was suspended in 
MeCN (20 ml), BSA (2.3 ml, 9.5 mmol) was added and the suspension was stirred until 
the solution became clear. The solution was then cooled to 0°C and 10b (500 mg, 1.9 
mmol, dissolved in 20 ml MeCN) and TMSOTf (1 ml, 3.9 mmol) were added. After 1 h 
at 0°C the mixture was allowed to warm to r.t. and the stirring was continued for 
another 16 h. It was diluted with ethyl acetate and washed with sat. NaHCO3. 
Purification by FC (ethyl acetate/hexane 4:1) yielded the desired nucleoside 14a/b (638 
mg, 1.5 mmol, 76%) in an anomeric ratio of α/β1.5:1 as a white foam. Rf 0.26 (ethyl 
acetate/hexane 4:1), HR-MS (NSI+, MeCN) for C22H23N3O7. calc: 442.1609, found: 
442.1617 (M + H+), 1H NMR (300 MHz, CDCl3) δ 8.87 (br, 2H), 7.92 (m, 4H), 7.63-
7.47 (m, 8H), 6.10 (m 2H), 5.20 (m, 2H), 5.03 (dd, 1H, J = 6.8, 3.2), 4.66 (d, 1H, J = 
5.7), 3.19 (dd, 1H, J = 14.8, 5.4), 2.91 (dd, 1H, J = 15.4, 6.5), 2.70 (m, 3H), 2.30 (m, 
1H), 2.25-2.11 (m, 5H), 2.07 (s, 3H), 2.04, 2.03 (2s, 6H), 1.99 (m, 1H), 1.93 (s, 3H). 13C 
NMR (101 MHz, MeOD) δ 172.40, 172.25, 172.03, 171.74, 164.98, 146.02, 145.77, 
134.66, 134.14, 134.12, 130.47, 129.84, 129.57, 129.17, 129.14, 123.36, 120.19, 98.89, 
98.11, 92.31, 92.07, 91.40, 90.17, 89.95, 89.44, 88.06, 87.65, 75.13, 61.55, 45.90, 
45.44, 44.12, 43.44, 38.32, 37.57, 21.47, 21.30, 20.90, 20.88, 20.86, 14.45. 
(3’S, 6’S)-1-(2’-Deoxy-3‘,5‘-ethano-α- and -β-D-ribofuranosyl] thymine 15a/b The 
nucleoside 12a/b (480 mg, 1.36 mmol) was dissolved in 0.2 M NaOH in 5:4:1 
THF/methanol/H2O (65 ml) at 0°C: The solution was stirred for one hour at 0°C and 
quenched by the addition of ammonium chloride. The solvents were then evaporated 
and the remains absorbed on silica gel. Purification by FC (10% methanol in DCM) 
yielded compound 15a/b (294 mg, 1.1 mmol, 81%) in an anomeric ratio of α/β~1.25:1 
as a white foam. Rf 0.19 (10% methanol in DCM), HR-MS (NSI
+, MeCN) for 
C12H16N2O5. Calc. 269.1132, found 268.1141 (M + H
+), 1H NMR (400 MHz, MeOD) δ 
7.74 (s, 1H), 7.40 (s, 1H), 6.10 (m, 2H), 4.55 (dd, 1H, J = 6.6, 1.9), 4.38 (m, 1H,), 4.28 
(m, 1H) 4.18 (dd, 1H, J = 6.7, 1.0), 2.52 (dd, 1H, J = 14.7, 7.1), 2.34 (m, 4H), 2.14 (m, 
1H), 2.05 (m, 2H), H-C(7’)), 1.90 (m, 3H), 1.89 (m, 3H), 1.88 (m, 2H), 1.80 (m, 1H), 
1.71 (m, 1H). 13C NMR (101 MHz, MeOD) δ 166.55, 166.22, 152.52, 152.23, 138.60 
(C-6), 137.07 (C-6), 111.98, 111.06, 91.65, 89.49 88.58, 86.24, 85.50, 84.89, 71.98, 
71.69, 49.33, 47.57, 46.94, 42.08, 41.15, 20.84, 12.51, 12.41. 
(3’S, 6’S)-N6-Benzoyl-9-(2’-deoxy-3‘,5‘-ethano-α- and -β-D-ribofuranosyl] adenine 
16a/b The nucleosides 13a/b (606 mg, 1.3 mmol) were dissolved in 0.2 M NaOH in 
5:4:1 THF/methanol/H2O (90 ml) at 0°C: The solution was stirred for one hour at 0°C 
and quenched by the addition of ammonium chloride. The solvents were then 
evaporated and the remains absorbed on silica gel. Purification by FC (10% methanol in 
DCM) yielded compound 16a/b (437 mg, 1.14 mmol, 88%) in anomeric ratio of 
α/β~1:1 as a white foam. Rf 0.2 (10% methanol in DCM), HR-MS (NSI
+, MeOH) for 
C19H19N5O4. calc: 382.1510, found: 382.1512 (M + H
+), 1H NMR (300 MHz, MeOD) δ 
8.76 (s, 1H), 8.70 (2s, 2H), 8.54 (s, 1H), 8.07 (m, 4H), 7.67-7.61 (m, 2H), 7.57-7.52 (m, 
4H), 6.51 (dd, 1H J = 7.2, 1.8), 6.33 (dd, 1H, J = 9.7, 5.3), 4.64-4.58 (m, 1H), 4.49 (d, J 
= 5.9), 4.37-4.26 (m, 2H), 2.91-2.83 (m, 2H), 2.72 (dd, 1H J = 14.9, 7.3), 2.59 (dd, 1H, 
J = 13.5, 5.3), 2.48-2.37 (m, 2H), 2.21-2.07 (m, 2H), 1.92-1.74 (m, 4H). 13C NMR (75 
MHz, MeOD) δ 153.36, 153.18, 152.95, 151.12, 151.08, 144.82, 144.29, 134.95, 
133.88, 129.74, 129.41, 91.51, 90.22, 86.86, 86.06, 85.82, 85.41, 71.74, 71.54, 47.85, 
47.03, 41.50, 41.32. 
(3’S, 6’S)-N6-Benzoyl-1-(2’-deoxy-3‘,5‘-ethano-α- and -β-D-ribofuranosyl] cytosine 
17a/b The nucleoside 14a/b (316 mg, 0.72 mmol) was dissolved in 0.2 M NaOH in 
5:4:1 THF/methanol/H2O (50 ml) at 0°C. The solution was stirred for one hour at 0°C 
and quenched by the addition of ammonium chloride. The solvents were then 
evaporated and the remains absorbed on silica gel. Purification by FC (10% methanol in 
DCM) yielded compound 17a/b (191 mg, 0.53 mmol, 74%) in an anomeric ratio of 
α/β~1:1 as a white foam. Rf 0.36 (10% methanol in DCM), HR-MS (NSI
+, MeCN) for 
C18H19N3O7. calc: 358.1397, found: 358.1387 (M + H
+), 1H NMR (300 MHz, MeOD) δ 
8.26 (d, 1H, J = 7.5), 8.18 (d, 1H, J = 7.5), 7.99 (m, 2H), 7.96 (m, 2H), 7.63 (m, 4H), 
7.55 (m, 4H), 6.10 (m, 2H), 4.72 (dd, 1H, J = 7.2, 2.1), 4.40-4.28 (m, 3H), 2.69 (dd, 1H, 
J = 13.7, 5.2), 2.59 (dd, 1H, J = 14.8, 6.7), 2.45 (dd, 1H, J = 14.8, 2.3), 2.38-2.29 (m, 
2H), 2.23 (m, 1H), 2.14 (m, 1H), 1.96-1.85 (m, 3H), 1.81-1.69 (m, 2H). 13C NMR (101 
MHz, MeOD) δ 164.81, 146.56, 146.10, 145.61, 134.74, 134.69, 134.10, 134.04, 
129.83, 129.82, 129.16, 129.11, 98.80, 97.96, 92.69, 91.59, 90.35, 88.28, 87.99, 87.32, 
85.96, 85.89, 82.54, 80.66, 79.66, 72.15, 71.89, 71.53, 58.32, 57.06, 57.01, 48.88, 
48.31, 46.79, 45.89, 43.79, 42.06, 41.63, 41.24, 18.36. 
(3’S, 6’S)-1-(2’-Deoxy-6’-O-(methylsulfonyl)-3‘,5‘-ethano-α- and -β-D-ribofuranosyl] 
thymine 18a/b A solution of 15a/b (294 mg, 1.09 mmol) was dissolved in pyridine (15 
ml) and cooled to 0°C. MsCl (85 μl, 1.09 mmol) was added and the mixture was stirred 
at 0°C and over night at 4°C. After quenching by the addition of sat. NaHCO3 and 
washing with ethyl acetate the combined organic layers were dried over MgSO4 and 
purified by FC (5% methanol in DCM) to yield 18a/b (250 mg, 0.72 mmol, 66%) in an 
anomeric ratio of α/β~1.25:1 as a white solid. Rf 0.45 (10% methanol in DCM), HR-MS 
(NSI+, MeOH) for C13H18N2O7S. Calc. 347.0907, found 347.0902 (M + H
+), 1H NMR 
(400 MHz, DMSO) δ 11.35 (s, 1H), 11.27 (s, 1H), 7.68(s, 1H), 7.55(s, 1H), 6.08 (m, 
2H), 5.18 (m, 1H), 5.07 (m, 1H), 4.50 (dd, 1H, J = 6.2, 2.0), 4.10 (dd, 1H, J = 7.1, 2.2), 
3.22 (s, 3H), 3.20 (s, 3H), 2.52 (m, 3H), 2.20 (m, 5H), 2.08 (m, 2H), 1.99 (m, 1H), 1.90 
(m, 1H), 1.81 (m, 3H), 1.79 (m, 3H). 13C NMR (101 MHz, DMSO) δ 163.80, 163.61, 
150.45, 150.43, 136.44, 135.96, 109.70, 109.11, 88.09 (C4’), 86.61 (C4’), 85.51 (C1’), 
84.10 (C1’), 83.45, 83.11, 80.49, 80.23, 45.40, 45.21, 45.05, 44.06, 38.32, 37.70, 37.55, 
37.42, 12.2, 12.11. 
(3’S, 6’S)-N6-Benzoyl-9-(2’-deoxy-, 6‘-O-(methylsulfonyl)-3’,5’-ethano-α- and -β-D-
ribofuranosyl] adenine (19a, 19b) A solution of 16a/b (153 mg, 0.4 mmol) was 
dissolved in pyridine (6 ml) and cooled to 0°C. MsCl (0.03 ml, 0.4 mmol) was added 
and the mixture was stirred for 2 h at rt. Silica was then added and the pyridine was 
evaporated and shortly high vac dried. FC (7% methanol in DCM) yielded the 
corresponding anomers 19a (105 mg. 0.23 mmol, 57%) and 19b (73 mg, 0.16 mmol, 
39%) as white foams. Analytical data for 19a: Rf 0.5 (10% methanol in DCM), HR-MS 
(NSI+, MeOH) for C20H21N5O6S. calc: 460.1285, found: 460.1272 (M + H
+), 1H NMR 
(400 MHz, MeOD) δ 8.74 (2s, 2H), 8.09 (m, 2H), 7.65 (m, 1H), 7.57 (m, 2H), 6.56 (dd, 
1H, J = 7.1, 2.6) , 5.21-5.14 (m, 1H), 4.59 (dd, 1H, J = 6.3, 1.5), 3.12 (s, 3H), 2.92 (dd, 
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1H, J = 14.9, 2.6), 2.84 (dd, 1H, J = 14.8, 7.2), 2.67 (ddd, 1H, J = 13.4, 6.5, 1.3), 2.40-
2.35 (m, 1H), 2.26-2.14 (m, 2H). 13C NMR (101 MHz, MeOD) δ 168.16, 153.11, 
151.22, 144.78, 138.41, 134.99, 133.92, 129.78, 129.43, 125.29, 90.39, 86.96, 85.87, 
81.13, 47.38, 47.26, 39.44, 38.11. Analytical data for 19b Rf 0.4 (10% methanol in 
DCM), HR-MS (NSI+, MeOH) for C20H21N5O6S. calc: 460.1285, found: 460.1273 (M + 
H+) 1H NMR (400 MHz, MeOD) δ 8.73 (s, 1H), 8.54 (s, 1H), 8.08 (m, 2H), 7.63 (m, 
1H), 7.55 (m, 2H), 6.37 (dd, 1H, J = 9.3, 5.9), 5.66-5.58 (m, 1H), 4.38 (dd, 1H, J = 6.9, 
1.8), 3.13 (s, 3H), 3.05 (m, 1H), 2.75 (ddd, 1H, J = 13.0, 6.2, 1.3), 2.63 (dd, 1H, J = 
13.8, 5.9), 2.43 (m, 1H), 2.20 (ddd, 1H, J = 14.1, 8.5, 7.0), 2.10 (dd, 1H, J = 13.0, 8.9). 
13C NMR (101 MHz, MeOD) δ 168.15, 153.20, 151.22, 144.75, 138.43, 134.96, 133.89, 
129.79, 129.75, 129.41, 125.56, 89.26, 86.34, 85.54, 81.11, 46.85, 46.41, 39.32, 38.16, 
18.39. 
(3’S, 6’S)-N6-Benzoyl-1-(2’-deoxy-, 6‘-O-(methylsulfonyl)-3’,5’-ethano-α- and -β-D-
ribofuranosyl] cytosine 20a/b A solution of 17a/b (415 mg, 1.16 mmol) in pyridine (16 
ml) was cooled to 0°C and MsCl (90 μl, 1.16 mmol) was added. The mixture was stirred 
overnight at 4°C. Sat. NaHCO3 was added and the aqueous phase was extracted with 
ethyl acetate. The crude product 20a/b precipitated in the organic phase and was used in 
the next experiment without further purification. Rf 0.49 (10% methanol in DCM), HR-
MS (NSI+, THF) for C19H21N3O7S. Calc. 436.1173, found 436.1172 (M + H
+) 1H NMR 
(400 MHz, DMSO) δ 11.21 (br, 2H), 8.23 (m, 2H), 8.00 (m, 4H), 7.62 (m, 2H), 7.51 (m, 
4H), 7.37 (m, 2H), 6.11 (dd, 1H, J = 9.3, 5.1), 6.04 (dd, 1H, J = 6.8, 2.7), 5.68 (s, 1H), 
5.53 (s, 1H), 5.20 (m, 1H), 5.10 (m, 1H), 4.67 (dd, 1H, J = 6.9, 2.3), 4.23 (dd, 1H, J = 
7.1, 1.9), 3.23 (s, 3H), 3.21 (s, 3H), 2.63 (dd, 1H, J = 14.5, 6.9), 2.47 (m, 2H), 2.31 (m, 
2H), 2.24 (m, 2H), 2.14 (m, 2H), 2.06 (m, 1H) 1.96 (m, 2H). 13C NMR (101 MHz, 
DMSO) δ 162.99, 145.29, 133.20, 132.74, 132.65, 128.45, 128.40, 95.63, 89.25, 88.90, 
87.29, 85.21, 83.76, 80.22, 79.86, 46.10, 45.99, 45.16, 45.10, 38.38, 37.71, 37.40, 
21.01. 
(3’S, 6’S)-1-(3’-O-Acetyl-2’-deoxy-6’-O-(methylsulfonyl)-3‘,5‘-ethano-α- and -β-D-
ribofuranosyl] thymine 21a/b A solution of 18a/b (250 mg, 0.72 mmol) in pyridine (7 
ml) was cooled to 0°C and DMAP (9 mg, 0.07 mmol) and Ac2O (0.08 ml, 0.8 mmol) 
were added. The mixture was stirred over night at r.t. and, after cooling to 0°C, 
carefully quenched and washed with sat. NaHCO3. The aqueous layers were extracted 
with DCM. The combined organic layers were dried over MgSO4 and evaporated. FC 
(3% methanol in DCM) yielded 21a/b (218 mg, 0.56 mmol, 78%) an anomeric ratio of 
α/β~1.25:1 as a white foam. Rf 0.49 (10% methanol in DCM), NSI pos (MeCN) for 
C15H20N2O8S. Calc. 389.1013, found 389.1019 (M + H
+) 1H NMR (400 MHz, CDCl3) δ 
7.24 (m, 1H), 7.06 (m, 1H), 6.11 (t, 1H, J = 6.2), 6.03 (dd, 1H, J = 9.2, 5.6), 5.24-5.15 
(m, 2H), 4.95 (dd, 1H, J = 6.2, 3.3), 4.58 (dd, 1H, J = 6.4, 1.4), 3.05, 3.03 (2s, 6H), 2.92 
(dd, 1H, J = 14.8, 6.6), 2.84 (m, 2H), 2.68 (dd, 1H, J = 15.3, 6.0), 2.54 (m, 2H), 2.48-
2.29 (m, 5H), 2.14 (m, 1H), 2.09, 2.07 (2s, 6H), 1.97 (m, 3H), 1.96 (m, 3H). 13C NMR 
(101 MHz, CDCl3) δ 170.02, 163.14, 162.93, 149.91, 149.81, 134.92, 134.66, 111.82, 
111.20, 90.48, 89.56, 86.93, 86.34, 84.73, 84.62, 79.91, 78.92, 77.33, 77.01, 76.69, 
44.27, 43.96, 43.89, 43.79, 38.55, 38.46, 37.24, 21.05, 12.68, 12.63. 
(3’S, 6’S)-N6-Acetyl-9-[3’-O-acetyl-2’-deoxy-6’-O-(methylsulfonyl)-3‘,5‘-ethano-β-D-
ribofuranosyl] –N6-benzoyladenine 22b A solution of 19b (195 mg, 0.42 mmol) in 
pyridine (12 ml) was cooled to 0°C and DMAP (5 mg, 42 μmol) and Ac2O (0.12 ml, 1.3 
mmol) were added. The mixture was stirred for 16 h at r.t. and, after cooling to 0°C, 
carefully quenched and washed with sat. NaHCO3. The aqueous layers were extracted 
with DCM. The combined organic layers were dried over MgSO4 and evaporated. FC 
(5% methanol in DCM) yielded 22b (192 mg, 0.38 mmol, 91%) as a white foam. Rf 0.8 
(10% methanol in DCM), HR-MS (NSI+, EtOAc) for C22H23N5O4S. calc: 502.1391, 
found: 502.11385 (M + H+), 1H NMR (400 MHz, CDCl3) δ 8.69 (s, 1H), 8.31 (s, 1H), 
7.71 (m, 2H), 7.42 (m, 1H), 7.32 (m, 2H), 6.42 (dd, 1H, J = 6.9, 2.9), 5.18 (m, 1H) 4.90 
(dd, 1H, J = 6.1, 1.7), 3.41 (m, 1H), 3.03 (s, 3H), 2.89 (m, 2H), 2.44 (m, 2H), 2.34 (m, 
1H), 2.09 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 175.38, 172.86, 172.05, 170.24, 
152.94, 152.53, 152.43, 151.16, 134.41, 133.07, 129.44, 129.01, 128.78, 90.34, 87.23, 
79.21, 44.41, 43.96, 38.65, 37.68, 25.61, 21.37. 
(3’S, 6’S)-N6-Acetyl-1-[3’-O-acetyl-2’-deoxy-6’-O-(methylsulfonyl)-3‘,5‘-ethano-α- 
and β-D-ribofuranosyl] –N6-benzoylcytosine 23a/b A solution of 20a/b (769 mg, 1.76 
mmol) in pyridine (35 ml) was cooled to 0°C and DMAP (22 mg, 0.18 mmol) and Ac2O 
(0.5 ml, 5.28 mmol) were added. The mixture was stirred for 20 h at rt and, after 
cooling to 0°C, carefully quenched and washed with sat. NaHCO3. The aqueous layers 
were extracted with DCM. The combined organic layers were dried over MgSO4 and 
evaporated. FC (5% methanol in DCM) yielded 23a/b (628 mg, 1.3 mmol, 75% over 
two steps) in an anomeric ratio of α/β~2:1as a white foam. Rf 0.9 (10% methanol in 
DCM), HR-MS (NSI+, EtOAc) for C21H23N3O8S. calc: 478.1279, found: 478.1268 (M + 
H+), 1H NMR (400 MHz, CDCl3) δ 7.93 (m, 6H), 7.61 (m, 4H), 7.55 (m, 4H), 6.10 (dd, 
1H, J = 6.4, 4.1), 6.04 (dd, 1H, J = 8.5, 5.6), 5.19 (m, 2H), 5.04 (dd, 1H, J = 5.9, 3.7), 
4.69 (d, 1H), 3.15 (m, 1H), 3.04 (s, 3H), 3.03 (s, 3H), 2.99 (m, 1H), 2.83-2.67 (m, 3H), 
2.50 (m, 2H), 2.35 (m, 4H), 2.08 (m, 6H), 2.04 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 
176.17, 170.32, 170.09, 163.25, 163.18, 154.73, 149.28, 144.01, 136.97, 133.47, 
132.99, 129.09, 128.19, 97.45, 96.72, 90.54, 90.08, 89.53 (C(1’)), 88.09, 86.89 , 85.77, 
79.77, 79.31, 45.55, 45.11, 44.25, 43.74, 38.64, 38.61, 38.58, 37.66, 29.87, 29.53, 
21.66, 21.53, 21.15. 
(3’S, 6’R)-1-(3’, 6’-Di-O-acetyl-2’-deoxy-3‘,5‘-ethano-α- and -β-D-ribofuranosyl] 
thymine 24a/b A solution containing 21a/b (301 mg, 0.77 mmol) and CsOAc (2.1 g, 
10.7 mmol) in DMSO (15 ml) was heated to 85°C and stirred for 16 h. After cooling to 
r.t. the mixture was diluted with ethyl acetate and washed with sat. NaHCO3. The 
combined organic layers were washed with H2O and dried over MgSO4. Via FC (5% 
methanol in DCM) 24a/b (254 mg, 0.72 mmol, 93 %) an anomeric ratio of α/β~1.25:1 
was obtained as a white foam. Rf 0.88 (10% methanol in DCM), HR-MS (NSI
+, MeOH) 
for C16H20N2O7. Calc. 353.1343, found 353.1341 (M + H
+) 1H NMR (400 MHz, CDCl3) 
δ 7.36 (m, 1H), 7.30 (m, 1H,), 6.41 (t, 1H, J = 6.4), 6.20 (dd, 1H, J = 9.7, 5.2), 5.43 (m, 
1H), 5.27 (m, 1H), 4.94 (dd, 1H, J = 6.8, 1.4), 4.62 (d, 1H, J = 6.8), 2.98 (m, 1H,), 2.84 
(dd, 1H, J = 14.3, 5.2), 2.55 (m, 2H), 2.43 (m, 1H), 2.38 (m, 3H), 2.30 (m, 1H), 2.15 (m, 
2H), 2.10, 2.09 (2s, 6H), 2.06-2.01 (m, 1H), 2.04, 2.03 (2s, 6H), 1.95 (m, 3H), 1.93 (m, 
3H). 13C NMR (101 MHz, CDCl3) δ 170.51, 170.27, 169.74, 163.97, 163.70, 150.64, 
150.52, 135.17, 134.65, 111.64, 111.37, 93.65, 93.53, 88.38, 87.53, 86.04, 83.88, 77.43, 
77.28, 75.10, 45.15, 45.04, 44.65, 44.36, 42.85, 38.75, 37.50, 21.76, 21.64, 21.40, 
12.86, 12.81. 
(3’S, 6’R)-N6-Benzoyl-9-(3’,6’-di-O-acetyl-2’-deoxy-3‘,5‘-ethano-β-D-ribofuranosyl] 
adenine 25b A solution containing 22b (219 mg, 0.41 mmol) and CsOAc (1.1 g, 6 
mmol) in DMSO (8 ml) was heated to 85°C and stirred for 16 h. After cooling to r.t. the 
mixture was diluted with ethyl acetate and washed with sat. NaHCO3. The combined 
organic layers were washed with H2O and dried over MgSO4. FC purification (5% 
methanol in DCM) yielded 325b (155 mg, 0.33 mmol, 81 %) as a white foam. Rf 0.75 
(10% methanol in DCM), HR-MS (NSI+, MeCN) for C23H23N5O6. calc: 466.1721, 
found: 466.1727 (M + H+), 1H NMR (400 MHz, CDCl3) δ 9.11 (br, 1H), 8.77 (s, 1H), 
8.28 (s, 1H), 8.03 (m, 2H), 7.60 (m, 1H), 7.52 (m, 2H), 6.61 (dd, 1H, J = 6.8, 3.1), 5.35 
(m, 1H), 4.96 (d, 1H), 3.33 (m, 1H), 3.14 (m, 1H), 2.40 (m, 4H), 2.11 (s, 3H), 1.96 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 170.38, 170.30, 152.85, 141.23, 141.15, 136.16, 
133.04, 130.49, 129.06, 128.15, 94.17, 89.59, 86.63, 86.10, 85.24, 76.29, 45.24 , 44.58, 
38.61, 37.99, 29.90, 21.58, 21.48. 
(3’S, 6’R)-N6-Benzoyl-1-(3’, 6’-Di-O-acetyl-2’-deoxy-3‘,5‘-ethano-α- and -β-D-
ribofuranosyl] cytosine 26a/b A solution containing 23a/b (523 mg, 1.09 mmol) and 
CsOAc (2.9 g, 15.1 mmol) in DMSO (20 ml) was heated to 85°C and stirred for 16 h. 
After cooling to r.t. the mixture was diluted with ethyl acetate and washed with sat. 
NaHCO3. The combined organic layers were washed with H2O and dried over MgSO4. 
The crude product 26a/b was used for the following step without purification. Rf 0.82 
(10% methanol in DCM), HR-MS (NSI+, EtOAc) for C22H23N3O7. calc: 442.1609, 
found: 442.1601 (M + H+) 
(3’S, 6’R)-1-(2’-Deoxy-3‘,5‘-ethano-α- and -β-D-ribofuranosyl] thymine 27a/b The 
nucleoside 24a/b (254 mg, 0.72 mmol) was dissolved in 0.2 M NaOH in 5:4:1 
THF/methanol/H2O (40 ml) at 0°C: The solution was stirred for one hour at 0°C and 
quenched by the addition of ammonium chloride. The solvents were then evaporated 
and the remains absorbed on silica gel. Purification by FC (10% methanol in DCM) 
yielded compound 27a/b (123 mg, 0.45 mmol, 64%) in anomeric ratio of α/β~1.25:1 as 
a white foam. Rf 0.2 (10% methanol in DCM), HR-MS (NSI
+, MeOH) for C12H16N2O5. 
Calc. 268.0951, found 268.0955 (M+), 1H NMR (400 MHz, DMSO) δ 11.25 (br, 2H), 
7.76 (s, 1H), 7.66 (s, 1H), 6.20 (m, 2H), 5.31 (s, 1H), 5.26 (s, 1H), 4.94 (d, 1H, J = 2.7), 
4.71 (d, 1H, J = 3.8), 4.39 (dd, 1H, J = 7.1, 3.0), 4.31 (m, 1H), 4.23 (m, 1H), 4.08 (m, 
1H), 2.62 (dd, 1H, J = 13.7, 6.9), 2.31 (m, 1H), 2.22 (m, 1H), 2.15 (m, 1H), 2.09 (m, 
1H), 2.02 (m, 2H)1.95(m, 1H), 1.85 (m, 1H), 1.80 (m, 3H), 1.76 (m, 3H), 1.77 (m, 2H), 
1.55 (m, 1H). 13C NMR (101 MHz, DMSO) δ 163.79, 163.63, 150.40, 150.36, 136.50, 
109.57, 109.13, 90.11, 89.98, 86.81, 86.10, 85.59, 83.66, 72.36, 70.90, 48.33, 47.92, 
46.80, 46.02, 41.32, 40.66, 12.34, 12.25. 
(3’S, 6’R)-N6-Benzoyl-9-(2’-deoxy-3‘,5‘-ethano-β-D-ribofuranosyl] adenine 28b The 
nucleoside 25b (115 mg, 0.25 mmol) was dissolved in 0.2 M NaOH in 5:4:1 
THF/methanol/H2O (17 ml) at 0°C: The solution was stirred for one hour at 0°C and 
quenched by the addition of ammonium chloride. The solvents were then evaporated 
and the remains absorbed on silica gel. Purification by FC (10% methanol in DCM) 
yielded compound 28b (80 mg, 0.21 mmol, 84%) as a white foam. Rf 0.3 (10% 
methanol in DCM), HR-MS (NSI+, MeOH) for C19H19N5O4. calc: 382.1510, found: 
382.1505 (M + H+), 1H NMR (300 MHz, MeOD) δ 8.71 (s, 1H), 8.65 (s, 1H), 8.09 (m, 
2H), 7.65 (m, 1H), 7.55 (m, 1H), 6.55 (dd, 1H, J = 9.3, 5.9), 4.50 (m, 1H), 4.38 (dd, J = 
6.9, 1.4, 1H), 3.01 (dd, 1H, J = 13.5, 9.4), 2.70 (dd, 1H, J = 13.6, 5.9), 2.33-2.24 (m, 
2H), 2.03 (m, 2H). 13C NMR (75 MHz, MeOD) δ 153.22, 153.09, 151.14, 144.27, 
134.98, 133.90, 129.76, 129.42, 125.05, 92.42, 88.68, 85.90, 74.93, 54.79, 49.46, 41.83. 
(3’S, 6’R)-N6-Benzoyl-1-(2’-deoxy-3‘,5‘-ethano-α- and -β-D-ribofuranosyl] cytosine 
29a/b The nucleoside 26a/b (386 mg, 0.87 mmol) was dissolved in 0.2 M NaOH in 
5:4:1 THF/methanol/H2O (50 ml) at 0°C: The solution was stirred for one hour at 0°C 
and quenched by the addition of ammonium chloride. The solvents were then 
evaporated and the remains absorbed on silica gel. Purification by FC (5% methanol in 
DCM) yielded compound 29a/b (183 mg, 0.51 mmol, 59% over two steps) in an 
anomeric ratio of α/β~2:1as a white foam. Rf 0.43 (10% methanol in DCM), HR-MS 
(NSI+, MeOH) for C18H19N3O5. calc: 380.1217, found: 380.1220 (M + Na
+), 1H NMR 
(400 MHz, MeOD) δ 8.46 (d, 1H, J = 7.5), 8.28 (d, 1H, J = 7.5), 7.98 (m, 4H), 7.63 (m, 
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4H), 7.54 (m, 4H), 6.33 (dd, 1H, J = 8.9, 5.8), 6.21 (dd, 1H, J = 6.8, 3.2), 4.68 (dd, 1H, 
J = 7.2, 3.1), 4.49 (m, 1H), 4.43 (m, 1H), 4.35 (d, 1H), 3.03 (dd, 1H, J = 14.4, 6.8), 2.67 
(dd, 1H, J = 13.6, 5.8), 2.37 (m, 3H), 2.24 (m, 1H), 2.15 (m, 1H), 2.09 (m, 2H), 2.04 (m, 
1H), 1.94 (m, 1H), 1.85 (m, 1H). 13C NMR (101 MHz, MeOD) δ 169.13, 164.79, 
157.92, 146.88, 146.56, 134.76, 134.72, 134.10, 134.06, 129.83, 129.17, 129.13, 98.76, 
98.06, 93.64, 92.52, 92.07, 88.92, 88.10, 87.97, 74.88, 73.43, 50.01, 48.88, 42.27, 
41.63. 
(3’S, 6’R)-1-{2’-Deoxy-6’-O-[(4,4’-dimethoxytriphenyl)methyl]-3‘,5‘-ethano-α- and -β-
D-ribofuranosyl}  thymine (30a, 30b) To a solution of nucleoside 27a/b (456 mg, 1.7 
mmol) in pyridine (8 ml) was added DMT-Cl (1.7 g 5.1 mmol) in three portions and it 
was stirred for 24 h at r.t. The solution was then diluted with ethyl acetate, washed with 
sat. NaHCO3 and dried over MgSO4. Purification by FC (2.5% methanol in DCM) 
yielded the corresponding anomers α and β, 30a (470 mg, 0.82 mmol, 48%) and 30b 
(384 mg, 0.67 mmol, 40%) resp., as pale yellow foams. Analytical data of 30: Rf 0.23 
(3% methanol in DCM), HR-MS (NSI+, MeCN) for C33H34N2O7. Calc. 593.2258, found 
593.2250 (M + Na+), 1H NMR (400 MHz, CDCl3) δ 7.47 (m, 2H), 7.35 (m, 4H), 7.29 
(m, 2H), 7.22 (m, 2H), 6.83 (m, 4H), 5.95 (dd, 1H, J = 7.8, 3.7), 4.40 (dd, 1H, J = 7.0, 
3.1), 4.24 (m, 1H), 3.79 (s, 6H), 2.89 (dd, 1H, J = 14.5, 7.8), 2.30 (dd, 1H, J = 14.5, 
3.7), 1.95 (m, 1H), 1.91 (m, 3H), 1.67 (m, 1H), 1.53 (m, 2H). 13C NMR (101 MHz, 
CDCl3) δ 163.87, 158.81, 150.59, 145.86, 138.45, 137.10, 136.98, 130.28, 130.25, 
128.28, 128.16, 127.04, 113.49, 110.80, 91.87, 91.50, 87.46, 87.22, 75.18, 55.45, 47.22, 
46.53, 46.39, 40.46, 12.63, 11.67. Analytical data of 30b, Rf 0.17 (3% methanol in 
DCM), HR-MS (NSI+, MeCN) for C33H34N2O7. Calc. 593.2258, found 593.2251 (M + 
Na+), 1H NMR (400 MHz, CDCl3) δ 8.69 (br, 1H), 7.45 (m, 2H), 7.35 (m, 4H), 7.32 (m, 
1H), 7.27 (m, 2H), 7.21 (m, 1H), 6.82 (m, 4H), 6.27 (dd, 1H, J = 8.8, 5.9), 4.33 (m, 1H), 
4.05 (dd, 1H, J = 7.5, 2.1), 3.78 (s, 6H), 2.49 (m, 2H), 2.10 (m, 1H), 1.77 (m, 2H), 1.50 
(m, 3H), 1.18 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 163.72, 158.91, 158.89, 150.54, 
145.65, 136.86, 136.66, 135.61, 130.22, 130.15, 128.34, 128.18, 127.18, 113.67, 
111.57, 89.85, 88.10, 87.68, 85.01, 76.40, 55.47, 46.99, 46.62, 46.08, 39.32, 12.31. 
(3’S, 6’R)-N6-Benzoyl-9-{2’-Deoxy-6’-O-[4,4’-(dimethoxytriphenyl)methyl]-3‘,5‘-
ethano- β-D-ribofuranosyl} adenine 31b To a solution of nucleoside 28b (80 mg, 0.21 
mmol) in pyridine (2 ml) was added DMT-Cl (213 mg 0.63 mmol) in three portions and 
the mixture was stirred for 24 h at r.t. The solution was then diluted with ethyl acetate, 
washed with sat. NaHCO3 and dried over MgSO4. Purification by FC (5% methanol in 
DCM) yielded compound 31b (129 mg, 0.19 mmol, 90%) as a white foam. Rf 0.42 
(10% methanol in DCM), HR-MS (NSI+, MeOH) for C40H37N5O6. calc: 684.2817, 
found: 684.2830 (M + H+), 1H NMR (400 MHz, CDCl3) δ 8.81 (s, 1H), 8.27 (s, 1H), 
8.04 (m, 2H), 7.61 (m, 1H,), 7.53 (m, 2H), 7.45 (m, 2H), 7.35 (m, 4H), 7.28 (m, 2H), 
7.22 (m, 1H), 6.81 (m, 4H), 6.46 (dd, 1H, J = 9.1, 5.4), 4.35 (m, 1H), 4.21 (dd, 1H, J = 
7.4, 3.5), 3.78 (s, 6H), 2.92 (dd, 1H, J = 13.2, 9.2), 2.64 (dd, 1H, J = 13.2, 5.5), 2.02 (m, 
1H), 1.83-1.58 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 171.37, 171.24, 158.84, 153.04, 
150.05, 149.74, 145.65, 141.30, 136.90, 136.87, 136.18, 132.97, 130.25, 129.09, 
128.28, 128.23, 128.11, 127.14, 123.95, 113.57, 90.02, 87.58, 87.17, 85.18, 77.43, 
75.85, 55.46, 47.26, 46.60, 46.08, 39.91. 
(3’S, 6’R)-N6-Benzoyl-1-{2’-Deoxy-6’-O-[4,4’-(dimethoxytriphenyl)methyl]-3‘,5‘-
ethano- α-and -β-D-ribofuranosyl] cytosine (32a, 32b) To a solution of nucleoside 
29a/b (394 mg, 1.1 mmol) in pyridine (6 ml) was added DMT-Cl (1.1 g 3.3 mmol) in 
three portions and it was stirred for 24 h at r.t. The solution was then diluted with ethyl 
acetate, washed with sat. NaHCO3 and dried over MgSO4. Purification by FC (ethyl 
acetate/hexane 4:1 to 5% methanol in DCM) yielded the corresponding anomers α and 
β, 32a (450 mg, 0.68 mmol, 62%) and 32b (217 mg, 0.33 mmol, 30%) as white foams. 
Analytical data for 32a: Rf 0.22 (ethyl acetate/hexane 4:1), HR-MS (NSI
+, MeCN) for 
C39H37N3O7. Calc: 660.2704, found: 660.2724 (M + H
+), 1H NMR (400 MHz, CDCl3) δ 
9.00 (br, 1H), 7.87 (m, 3H), 7.55 (m, 1H), 7.46 (m, 5H), 7.36 (m, 4H), 7.26 (m, 2H), 
7.21 (m, 1H), 6.83 (m, 4H), 6.05 (dd, 1H, J = 7.1, 2.1), 4.48 (dd, 1H, J = 7.3, 3.8), 4.25 
(m, 1H), 3.79 (s, 6H), 3.03 (dd, 1H), 2.64 (dd, 1H, J = 14.8, 2.0), 1.64 (m, 3H). 13C 
NMR (101 MHz, ) δ 162.60, 158.72, 155.27, 146.01, 145.82, 137.07, 137.03, 133.27, 
133.14, 130.26, 129.08, 128.32, 128.10, 127.87, 126.98, 113.43, 96.20, 93.05, 92.81, 
87.17, 86.83, 75.04, 60.59, 55.40, 47.40, 46.27, 40.51, 21.22, 14.37. Analytical data for 
43b: Rf 0.05 (ethyl acetate/hexane 4:1), HR-MS (NSI
+, MeCN) for C39H37N3O7. Calc: 
660.2704, found: 660.2704 (M + H+), 1H NMR (300 MHz, CDCl3) δ 8.77 (br, 1H), 
8.23 (m, 1H), 7.89 (m, 2H), 7.60 (m, 1H), 7.51 (m, 4H), 7.37-7.19 (m, 8H), 6.84 (m, 
4H), 6.45 (dd, 1H, J = 8.6, 5.5), 4.37 (m, 1H), 4.23 (d, 1H, J = 5.8), 3.79, 3.77 (2s, 6H), 
2.84 (dd, 1H, J = 13.5, 5.4), 2.36 (dd, 1H, J = 13.5, 8.7), 1.88- 1.73 (m, 3H), 1.42 (m, 
1H). 13C NMR (126 MHz, CDCl3) δ 158.87, 158.37, 145.45, 136.83, 136.71, 133.38, 
130.28, 130.20, 129.26, 128.35, 128.31, 127.76, 127.17, 113.62, 113.51, 90.84, 89.31, 
88.06, 87.68, 87.12, 76.79, 55.43, 55.42, 47.10, 39.46. 
(3’S, 6’R)-1-{6’-O-[(2-Cyanoethoxy)(diisopropylamino)phosphino]-2’-deoxy-6’-O-
[(4,4’-dimethoxytriphenyl)methyl]-3‘,5‘-ethano- β-D-ribofuranosyl} thymine 33b 
Compound 30b (163 mg, 0.29 mmol) was dissolved in MeCN (2.5 ml) and Hünig’s 
base (0.24 ml, 1.43 mmol) and Cep-Cl (0.19 ml, 0.87 mmol) were added. The solution 
was stirred at r.t. for 1 h, diluted with ethyl acetate and washed with sat. NaHCO3. The 
aqueous layer is extracted with ethyl acetate and dried over MgSO4. Purification by FC 
(ethyl acetate/hexane 1:1) yielded phosphoramidite 33b (214 mg, 0.24 mmol, 72%) as a 
white foam. 31P-NMR showed no phosponate peak, therefore no further purification was 
necessary. Rf 0.63 (ethyl acetate/hexane 2:1), HR-MS (NSI
+, MeCN) for C42H51N4O8P. 
Calc. 771.3517, found 771.3531 (M + H+), 1H NMR (400 MHz, CDCl3) δ 8.11 (br, 1H), 
7.45 (m, 2H), 7.35 (m, 4H), 7.27 (m, 4H), 7.20 (m, 1H), 6.82 (m, 4H), 6.23 (dd, 1H, J = 
9.6, 4.9), 4.33 (m, 1H), 4.27 (dd, 1H, J = 14.8, 7.5), 3.79 (m, 6H), 3.80-3.55 (m, 4H), 
2.85 (m, 1H), 2.64 (m, 1H), 2.58 (t, 1H, J = 6.3), 2.52 (m, 1H), 2.19 (m, 2H), 1.70 (m, 
1H), 1.50 (m, 3H), 1.16 (m, 9H), 1.10 (m, 3H), 1.05 (m, 1H). 13C NMR (101 MHz, 
CDCl3) δ 163.59, 158.89, 150.19, 145.61, 136.87, 136.59, 135.70, 130.24, 130.14, 
128.35, 128.19, 127.18, 113.69, 111.30, 91.69, 89.46, 88.19, 85.18, 77.44, 76.32, 76.20, 
60.62, 58.17, 57.99, 55.47, 43.66, 43.51, 38.94, 38.85, 24.76, 24.53, 24.45, 20.56, 
14.41, 12.30, 12.26. 31P NMR (122 MHz, CDCl3) δ 142.13, 141.81. 
(3’S, 6’R)-N6-Benzoyl-9-{3’-O-[(2-cyanoethoxy)(diisopropylamino)phosphino]-2’-
deoxy-6’-O-[4,4’-dimethoxytriphenyl)methyl]-3‘,5‘-ethano- β-D-ribofuranosyl} adenine 
34b Compound 31b (290 ng, 0.42 mmol) was dissolved in MeCN (4 ml) and Hünig’s 
base (0.36 ml, 2.1 mmol) and Cep-Cl (0.28 ml, 1.3 mmol) were added. The solution was 
stirred at r.t. for 1 h, diluted with ethyl acetate and washed with sat. NaHCO3. The 
aqueous layer was extracted with ethyl acetate and the organig layers dried over 
MgSO4. Purification by FC (ethyl acetate/hexane 1:1) yielded phosphoramidite 34b 
(310 mg, 0.35 mmol, 83%) as a white foam. 31P-NMR showed a H-phosphonate peak. 
Compound 34b had therefore to be further purified. 34b was dissolved in 1 ml of DCM 
and added dropwise to icecold hexane. The filter cake is collected by washing the filter 
with DCM and evaporate the solvent. 31P-NMR showed no more phosphonate so the 
pure phosphoramidite 34b (325 mg, 0.37 mmol, 87%) could be collected. Rf 0.48 (ethyl 
acetate/hexane 2:1), HR-MS (NSI+, MeCN) for C49H54N7O7P. calc: 884.3901, found: 
884.3902 (M + H+), 1H NMR (300 MHz, CDCl3) δ 9.07 (s, 1H), 8.83 (d, 1H, J = 3.2), 
8.26 (s, 1H), 8.04 (m, 2H), 7.61 (m, 1H), 7.55 (m, 2H)), 7.46 (m, 2H), 7.36 (m, 4H), 7.32 
(m, 2H), 6.82 (m, 4H), 6.45 (m, 1H), 4.36 (m, 2H), 3.78 (s, 6H), 3.74-3.54 (m, 4H), 3.05 
(m, 2H), 2.63 (t, 1H, J = 6.3), 2.55 (t, 1H, J = 6.3), 2.08 (m, 1H), 1.90 (m, 2H), 1.50 (m, 
1H), 1.16 (m, 9H,), 1.10 (d, J = 6.8, 3H). 13C NMR (101 MHz, CDCl3) δ 164.71, 
158.73, 153.02, 151.71, 145.59, 141.41, 141.28, 136.85, 136.80, 134.02, 132.86, 
130.21, 130.16, 129.02, 128.22, 128.15, 128.00, 127.02, 123.21, 117.78, 117.72, 
113.49, 91.16, 91.07, 91.04, 90.95, 89.89, 89.71, 89.68, 89.64, 87.60, 87.55, 85.26, 
85.11, 77.36, 75.67, 75.53, 58.11, 58.03, 57.93, 57.85, 55.38, 45.48, 45.40, 45.12, 
43.60, 43.56, 43.48, 43.43, 39.35, 39.32, 24.73, 24.67, 24.50, 24.47, 24.39, 20.56, 
20.48, 20.40. 31P NMR (122 MHz, CDCl3) δ 142.13, 142.07. 
(3’S, 6’R)-N6-Benzoyl-1-{3’-O-[(2-cyanoethoxy)(diisopropylamino)phosphino]-2’-
deoxy-6’-O-[4,4’-dimethoxytriphenyl)methyl]-3‘,5‘-ethano- β-D-ribofuranosyl} 
cytosine 35b Compound 32b (216 mg, 0.33 mmol) was dissolved in MeCN (3 ml) and 
Hünig’s base (0.28 ml, 1.6 mmol) and Cep-Cl (0.22 ml, 0.99 mmol) were added. The 
solution was stirred at r.t. for 2 h, diluted with ethyl acetate and washed with sat. 
NaHCO3. The aqueous layer was extracted with ethyl acetate and dried over MgSO4. 
Purification by FC (ethyl acetate/hexane 1:1) yielded phosphoramidite 35b (214 mg, 
0.24 mmol, 72%) as a white foam. 31P-NMR showed a phosponate peak. Compound 
35b had therefore to be further purified. 35b was dissolved in 1 ml of DCM and added 
dropwise to icecold hexane. The filter cake is collected by washing the filter with DCM 
and evaporate the DCM. After three cycles and another FC 31P-NMR showed no more 
phosphonate so the pure phosphoramidite 35b could be collected. Rf 0.4 (ethyl 
acetate/hexane 2:1), HR-MS (NSI+, THF) for C48H54N5O8P. calc: 860.3788, found: 
860.3789 (M + H+), 1H NMR (400 MHz, CDCl3) δ 8.70 (br, 1H), 8.20 (m, 1H), 7.90 (m, 
2H), 7.62 (m, 1H), 7.52 (m, 2H), 7.44 (m, 2H), 7.33 (m, 5H), 7.25 (m, 3H), 6.84 (m, 
4H), 6.24 (m, 1H), 4.40 (m, 2H), 3.78 (2s, 6H), 3.77-3.53 (m, 4H), 3.11 (dd, 1H, 13.9, 
4.7), 2.65 (t, 1H, J = 6.3), 2.57 (t, 1H, J = 6.4), 2.38 (m, 1H), 2.09 (m, 1H), 1.85 (m, 
1H), 1.81 (m, 1H), 1.44 (m, 1H) 1.15 (m, 9H), 1.08 (m, 3H), 13C NMR (101 MHz, 
CDCl3) δ 162.21, 158.87, 158.84, 145.37, 136.79, 136.63, 133.33, 130.26, 130.16, 
129.25, 128.32, 127.75, 127.17, 113.63, 91.68, 91.59, 91.52, 91.43, 90.40, 90.34, 90.17, 
90.10, 88.12, 88.09, 87.38, 87.34, 77.43, 76.44, 76.43, 58.25, 58.08, 58.00, 55.48, 
55.42, 46.98, 46.96, 46.74, 46.64, 46.56, 46.33, 46.25, 45.79, 45.68, 43.64, 43.51, 
39.09, 24.79, 24.72, 24.53, 24.47, 24.40, 24.21, 24.13, 24.10, 22.54, 20.54, 20.50, 
20.46, 20.42, 14.41, 14.33. 31P NMR (122 MHz, CDCl3) δ 149.96, 149.68. 
(3R, 5S, 7S)-3-methoxyoctahydropentalene-7,5-diol 36b The sugar 10b (1.0 g, 3.6 
mmol) was dissolved in 0.2 M NaOH in 5:4:1 THF/methanol/H2O (150 ml) at 0°C. The 
solution was stirred for one hour at 0°C and quenched by the addition of ammonium 
chloride. The solvents were then evaporated and the remains absorbed on silica gel. 
Purification by FC (5% methanol in DCM) yielded compound 36b (618 mg, 3.5 mmol, 
97%) as a colorless oil. Rf 0.14 (ethyl acetate/hexane 1:1), HR-MS (NSI
+, MeOH) for 
C8H14O4. Calc. 197.0784, found 197.0788 (M + Na
+), 1H NMR (300 MHz, MeOD) δ 
4.98 (dd, 1H, J = 5.8, 2.0), 4.40 (m, 1H), 4.23 (dd, 1H, = 6.7, 2.3), 3.27 (s, 3H), 2.27 (m, 
2H), 2.00 (m, 1H), 1.94 (m, 1H), 1.85 (m, 1H), 1.74 (dd, 1H, J = 13.0, 7.9). 13C NMR 
(75 MHz, MeOD) δ 107.38, 90.61, 86.83, 72.44, 55.27, 49.70, 48.90, 42.88. 
tert-butyl(((3R,5S,7S)-3-methoxy-7-(((2,3,3-trimethylbutan-2 
yl)silyl)oxy)octahydropentalen-3a-yl)oxy)dimethylsilane 37b Compound 36b (1.7 g, 
10.0 mmol) was dissolved in DMF (40 ml). TBSCl (3.8 g, 25.0 mmol) and imidazole 
(2.1 g, 30.0 mmol) were added and the mixture was stirred at 85°C for 2 d. The solution 
was then diluted with ethyl acetate,washed with brine and H2O and dried over MgSO4. 
Purification by FC (ethyl acetate/hexane 3:1) yielded 46 (3.3 g, 8.2 mmol, 82%) as a 
colorless oil. Rf 0.9 (ethyl acetate/hexane 1:1), HR-MS (NSI
+, THF) for C20H42O4Si2. 
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Calc. 403.2694, found 403.2693 (M + H+), 1H NMR (300 MHz, CDCl3) δ 4.99 (dd, 1H, 
J = 5.7, 2.2), 4.49 (m, 1H), 4.25 (d, 1H, J = 6.4), 3.33 (s, 3H), 2.33 (m, 2H), 2.00 (m, 
2H), 1.77 (m, 2H), 0.88 (m, 18H), 0.08 (m, 12H). 13C NMR (101 MHz, CDCl3) δ 105.87 
(C(3)), 89.93 ((C1)), 71.85 (C(7)), 55.13 (OMe), 50.60 (C(4)), 49.47 (C(6)), 41.98 
(C(8)), 26.08 (TBS), 25.89 (TBS), 18.42 (TBS), 17.99 (TBS), -2.50 (TBS), -2.55 (TBS). 
(3’S, 6’S)- )-2-amino-6-chloro-9-{3’, 6’-di-O-[(tert-butyl)-dimethylsilyl]-2’-deoxy-
3‘,5‘-ethano-α- and -β-D-ribofuranosyl} purine 38a/b To a suspension of 2’-amino-6’-
chloropurine (814 mg, 4.8 mmol) in MeCN (11 ml) was added BSA (2.3 ml. 9.6 mmol). 
The mixture was stirred at r.t. until a clear solution appeared. Compound 46 (858 mg, 
2.1 mmol, in 5 ml MeCN) and TMSOTf (0.13 ml, 0.72 mmol) was then added and the 
mixture was stirred for 6 h at 55°C. The brownish solution was diluted by the addition 
of ethyl acetate, washed with sat. NaHCO3 and dried over MgSO4. Purification by FC 
(ethyl acetate/hexane 1:3) yielded 38b (411 mg, 0.76 mmol, 36%) and 38a (316 mg, 
0.58 mmol, 28%) as white foams. Analytical data of 38b: Rf 0.4 (hexane/ethyl acetate 
3:1), HR-MS (NSI+, EtOAc) for C24H43N5O3ClSi2. Calc: 540.2587, found: 540.2608 (M 
+ H+), 1H NMR (400 MHz, CDCl3) δ 7.87 (s, 1H), 6.00 (dd, 1H, J = 9.1, 5.6), 5.13 (br, 
2H), 4.40 (m, 1H), 4.31 (d, 1H, J = 6.3), 2.54 (m, 2H), 2.34 (m, 1H), 2.12 (m, 1H), 1.84 
(m, 2H), 0.90 (m, 18H), 0.16 (m, 6H), 0.08 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 
159.18, 153.72, 151.77, 140.60, 126.19, 89.88, 86.42, 83.86, 71.80, 48.95, 47.24, 40.71, 
26.05, 25.87, 18.33, 18.03, -2.37, -2.45, -4.42, -4.48. Analytical data of 38a: Rf 0.26 
(hexane/ethyl acetate 3:1), HR-MS (NSI+, EtOAc) for C24H43N5O3ClSi2. Calc: 
540.2587, found: 540.2607 (M + H+), 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 6.24 
(dd, 1H, J = 7.1, 1.6), 5.11 (br, 2H), 4.45 (d, 1H, J = 6.1), 4.25 (m, 1H), 2.85 (dd, 1H, J 
= 14.6, 1.5), 2.48 (dd, 1H, = 14.6, 1.5), 2.30 (m, 1H), 2.12 (m, 1H), 1.90 (m, 1H), 1.81 
(m, 1H), 0.89, 0.80 (2s, 18H3), 0.12 (s, 3H), 0.07 (s, 6H), 0.02 (s, 3H). 
13C NMR (101 
MHz, CDCl3) δ 159.15, 153.63, 151.52, 141.11, 125.92, 91.16, 86.93, 84.80, 71.49, 
50.35, 48.48, 40.79, 26.04, 25.79, 18.31, 17.97, -2.26, -2.55, -4.47, -4.56. 
(3’S, 6’S)- )-9-{3’,6’-di-O-[(tert-butyl)-dimethylsilyl]-2’-deoxy-3’,5’-ethano-α- and -β-
D-ribofuranosyl} guanine 39a/b To a solution of 3-hydroxypropionitrile (0.4 ml, 5.9 
mmol) in THF (8 ml) at 0°C was carefully added NaH (60%, 285 mg, 7.1 mmol) and 
the suspension was stirred for 1 h at r.t. The anomeric compound 38a/b (700 mg, 1.3 
mmol in 8 ml THF) was added and the brown mixture was stirred for another 3 h at r.t. 
Addition of silica, evaporation of the solvents and filtration (10% methanol in DCM) 
over a patch of silica yielded the crude product 39a/b. The brown foam was used 
without further purification in the next step. Rf 0.5 (10% methanol in DCM), HR-MS 
(NSI+, MeCN) for C24H43N5O4Si2. Calc. 521.81, found 522.29 (M + H
+) 
(3’S, 6’S)- N2-{N,N-Dimethylformamidino}-9-{3’,6’-di-O-[(tert-butyl)-dimethylsilyl]-
2’-deoxy-3’,5’-ethano-α- and -β-D-ribofuranosyl} guanine 40a/b The crude compound 
39a/b (750 mg, ~1.4 mmol) was dissolved in DMF (12 ml) and N,N-
dimethylformamide dimethyl acetale (0.37 ml, 2.8 mmol) was added. The clear yellow 
solution was stirred for 2 h at 55°C. The solvent was evaporated via Kugelrohr 
distillation and purified by FC (5% methanol in DCM) to obtain nucleoside 40a/b (715 
mg, 1.2 mmol, 71% over 2 steps) in an anomeric ratio of α/β~2:1as yellow oil. Rf 0.5 
(10% methanol in DCM), HR-MS (NSI+, EtOAc) for C27H49N6O4Si2. Calc: 577.3348, 
found: 577.3339 (M + H+), 1H NMR (300 MHz, MeOD) δ 8.66 (s, 1H), 8.62 (s, 1H), 
8.01 (2s, 2H), 6.25 (dd, 1H, J = 6.8, 1.7), 6.14 (dd, 1H, J = 9.6, 5.1), 4.57 (d, 1H, J = 
6.1), 4.45 (m, 1H), 4.34 (m, 2H), 3.20 (m, 6H) , 3.12 (m, 6H), 2.99 (s, 1H), 2.86 (m, 2H), 
2.64-2.36 (m, 5H), 2.12 (m, 2H), 1.85 (m, 4H), 0.96 (s, 18H), 0.92 (2s, 18H), 0.77 (m, 
12H), 0.21 (m, 12H). 13C NMR (75 MHz, CDCl3) δ 158.38, 158.28, 158.22, 157.10, 
156.90, 150.37, 135.72, 118.34, 120.54, 90.85, 89.89, 87.00, 86.54, 84.23, 82.88, 77.43, 
71.95, 71.65, 58.07, 48.82, 48.72, 41.56, 40.80, 35.43, 26.02, 25.90, 25.83, 21.70, 
18.27, 18.06, 18.00, -2.29, -2.46, -2.52, -4.47, -4.54. 
(3’S, 6’S)- N2-{N,N-Dimethylformamidino}-9-{3’-O-[(tert-butyl)-dimethylsilyl]-2’-
deoxy-3’,5’-ethano-α- and -β-D-ribofuranosyl} guanine 41a/b A solution of 40a/b (1.5 
g, 2.6 mmol) in THF (20 ml) was cooled to 0°C. HF/Et3N (37% HF, 1.7 ml, 3.9 mmol) 
was added and allowed to warm to r.t. The reaction mixture was stirred at r.t. over night 
and then quenched with silica. The solvent was evaporated and the crude mixture 
purified by FC (5% methanol in DCM). 41a/b (658 mg, 1.4 mmol, 55%) in an anomeric 
ratio of α/β~2:1was obtained as a white foam. Rf 0.5 (10% methanol in DCM), HR-MS 
(NSI+, MeCN) for C21H34N6O4Si. Calc: 463.2484, found: 463.2472 (M + H
+), 1H NMR 
(400 MHz, MeOD) δ 8.66 (s, 1H), 8.62 (s, 1H), 8.01 (s, 1H), 7.97 (s, 1H), 6.24 (dd, 1H, 
J = 6.7, 1.6), 6.09 (dd, 1H, J = 10.0, 5.1), 4.59 (m, 1H), 4.53 (m, 1H), 4.30 (m, 1H), 4.25 
(m, 1H), 3.21 (m, 6H), 3.12 (m, 6H), 2.92 (dd, 1H, J = 14.6, 1.6), 2.71 (m, 1H), 2.60 (m, 
2H), 2.49 (m, 1H), 2.41 (m, 1H), 2.15 (m, 2H), 1.89-1.79 (m, 4H), 0.95 (s, 9H), 0.76 (s, 
9H), 0.22 (m, 6H), 0.12 (s, 3H), -0.02 (s, 3H). 13C NMR (101 MHz, MeOD) δ 160.16, 
159.69, 159.62, 159.00, 158.85, 151.96, 151.43, 138.82, 138.31, 121.07, 120.95, 92.76, 
91.03, 88.52, 88.12, 87.23, 84.98, 71.63, 71.39, 50.21, 47.74, 41.62, 41.45, 41.18, 
40.91, 35.34, 26.24, 26.07, 18.73, 18.56, -2.41, -2.45, -2.48, -2.75. 
(3’S, 6’S)- N2-{N,N-Dimethylformamidino}-9-{6’-O-(methylsulfonyl)-3’-O-[(tert-butyl)-
dimethylsilyl]-2’-deoxy-3’,5’-ethano-α- and -β-D-ribofuranosyl} guanine 42a/b A 
solution of 41a/b (243 mg, 0.53 mmol) in pyridine (5.5 ml) was cooled to 0°C and 
MsCl (40 μl, 0.58 mmol) was added. The mixture was stirred for 4 h at r.t. After the 
addition of silica the pyridine was evaporated and the crude product purified by FC (5% 
methanol in DCM). Compound 42a/b (263 mg, 0.49 mmol, 92%) in an anomeric ratio 
of α/β~2:1was obtained as a white solid. Rf 0.4 (10% methanol in DCM), HR-MS 
(NSI+, EtOAc) for C22H36N6O6SSi. Calc: 540.2186, found: 541.2183 (M
+), 1H NMR 
(400 MHz, CDCl3) δ 8.62 (s, 1H, N=CHN(CH3)2), 8.53 (s, 1H), 7.93 (s, 1H), 7.79 (s, 
1H), 6.24 (dd, 1H, J = 7.1, 3.7), 6.04 (dd, 1H, J = 9.4, 5.4), 5.24-5.13 (m, 2H), 4.54 (d, 
1H, J = 5.4), 4.35 (dd, 1H, J = 6.9, 1.6), 3.20 (s, 3H), 3.18 (s, 3H), 3.11 (s, 6H), 3.05 (s, 
3H), 3.04 (s, 3H), 2.72 (m, 2H), 2.61 (m, 4H), 2.42 (m, 2H), 2.26-2.12 (m, 4H), 0.92 (s, 
9H), 0.87 (s, 9H), 0.19 (s, 3H), 0.18 (s, 3H), 0.15 (s, 3H), 0.08 (s, 3H). 13C NMR (101 
MHz, CDCl3) δ 158.06, 157.99, 156.93, 150.34, 136.75, 136.43, 121.20, 89.19, 88.54, 
86.97, 86.46, 83.87, 79.69, 79.22, 47.39, 47.30, 46.53, 46.39, 41.70, 38.59, 38.00, 
37.84, 35.50, 25.83, 25.80, 18.04, -2.46, -2.48. 
(3’S, 6’R)- N2-{N,N-Dimethylformamidino}-9-{6’-O-acetyl-3’-O-[(tert-butyl)-
dimethylsilyl]-2’-deoxy-3’,5’-ethano-α- and -β-D-ribofuranosyl} guanine 43a/b A 
solution containing 42a/b (620 mg, 1.15 mmol) and CsOAc (3.0 g, 15.9 mmol) in 
DMSO (16 ml) was heated to 85°C and stirred for 16 h. After cooling to r.t. the mixture 
was diluted with ethyl acetate and washed with sat. NaHCO3. The combined organic 
layers were washed with H2O and dried over MgSO4. By FC purification (5% methanol 
in DCM) 43a/b (491 mg, 0.97 mmol, 85 %) was obtained in an anomeric ratio of 
α/β~2:1 as a white foam. 1H-NMR showed still a considerable amount of DMSO. Rf 0.5 
(10% methanol in DCM), HR-MS (NSI+, EtOAc) for C23H36N6O5Si. Calc: 505.2589, 
found: 505.2582 (M + H+), 1H NMR (400 MHz, CDCl3) δ 9.72 (br, 2H), 8.60 (s, 1H), 
8.58 (s, 1H), 7.95 (s, 1H), 7.89 (s, 1H), 6.32 (m, 1H), 6.22 (m, 1H), 5.34 (m, 2H), 4.59 
(m, 1H), 4.36 (dd, 1H, J = 6.9, 1.3), 3.17 (m, 6H), 3.10 (m, 6H), 2.70-2.53 (m, 4H), 
2.41- 2.28 (m, 6H) 2.16 (m, 2H), 2.06 (s, 3H) , 2.05 (s, 3H),  0.90 (s, 9H), 0.87 (s, 9H,), 
0.14 (m, 12H). 13C NMR (101 MHz, CDCl3) δ 170.49, 158.39, 158.13, 157.17, 156.95, 
150.16, 136.83, 135.83, 132.06, 120.35, 95.82, 91.14, 91.03, 89.43, 89.36, 84.92, 83.83, 
76.72, 76.30, 48.04, 46.85, 46.22, 45.88, 41.57, 37.76, 37.59, 35.40, 25.85, 25.80, 
25.74, 21.52, 21.40, 17.99, -2.56, -2.63, -2.73. 
(3’S, 6’R)- 9-{3’-O-[(tert-butyl)-dimethylsilyl]-2’-deoxy-3’,5’-ethano-α- and -β-D-
ribofuranosyl} guanine (44a, 44b) The anomeric mixture 43a/b (512 mg, 1.0 mmol) 
was dissolved in 1 M KOH in 5:3 methanol/H2O (12 ml). The solution was stirred for 6 
h at 60°C and quenched by the addition of ammonium chloride. The solvents were then 
evaporated and the remains absorbed on silica gel. Purification by FC (5% methanol in 
DCM) yielded the anomers 44b (170 mg, 0.42 mmol, 42%) and 44a (78 mg, 0.2 mmol, 
20%) as white solids. Analytical data for 44a: Rf 0.27 (10% methanol in DCM), HR-MS 
(NSI+, MeOH) for C18H29N5O4Si. Calc. 408.2062, found 408.2056 (M + H
+), 1H NMR 
(400 MHz, MeOD) δ 7.96 (s, 1H), 6.19 (dd, 1H, J = 9.5, 5.7), 4.48 (m, 1H), 4.34 (dd, 
1H, J = 7.0, 1.7), 2.93 (dd, 1H, J = 13.4, 9.6), 2.59 (dd, 1H, J = 13.4, 5.7), 2.26 (m, 2H), 
2.08 (dd, 1H, J = 13.7, 5.4), 1.95 (m, 1H), 0.93 (s, 9H), 0.19 (s, 3H), 0.17 (s, 3H). 13C 
NMR (101 MHz, MeOD) δ 159.29, 155.44, 152.66 137.90, 117.66, 93.15, 91.18, 85.41, 
74.81, 49.30, 41.34, 26.18, 18.69, -2.53, -2.59. Analytical data for 44b: TLC Rf 0.27 
(10% methanol in DCM), HR-MS (NSI+, MeOH) for C18H29N5O4Si. Calc. 408.2062, 
found 408.2057 (M + H+), 1H NMR (400 MHz, MeOD) δ 7.89 (s, 1H), 6.26 (dd, 1H, J = 
6.7, 3.0), 4.66 (dd, 1H, J = 7.0, 2.0), 4.45 (m, 1H), 2.95 (dd, 1H, J = 13.9, 6.7), 2.75 (dd, 
1H, J = 13.9, 3.0), 2.31 (m, 1H), 2.14 (m, 2H), 1.84 (m, 1H), 0.78 (s, 9H), 0.11 (s, 3H), -
0.02 (s, 3H). 13C NMR (101 MHz, MeOD) δ 159.33, 155.17, 152.30, 137.30, 118.09, 
94.21, 91.23, 88.09, 74.20, 49.66, 48.90, 41.35, 26.06, 18.57, -2.56, -2.89. 
(3’S, 6’R)- N2-{N,N-Dimethylformamidino}-9-{3’-O-[(tert-butyl)-dimethylsilyl]-2’-
deoxy-3’,5’-ethano-β-D-ribofuranosyl} guanine 45b The nucleoside 44b (170 mg, 0.41 
mmol) was dissolved in DMF (4.5 ml) and N,N-dimethylformamid dimethyl acetale 
(0.11 ml, 0.82 mmol) was added. The solution was stirred for 3h at 55°C. The DMF was 
then evaporated by Kugelrohr distillation and the crude product purified by FC (10% 
methanol in DCM). Compound 45b (122 mg, 0.26 mmol, 64%) was obtained as a white 
foam. Rf 0.3 (10% methanol in DCM), HR-MS (NSI
+, MeCN) for C21H34N6O4Si. Calc. 
463.2484, found 463.2475 (M + H+), 1H NMR (400 MHz, CDCl3) δ 9.13 (s, 1H), 8.68 
(s, 1H), 7.87 (s, 1H), 6.04 (dd, 1H, J = 10.0, 5.5), 4.53 (m, 1H), 4.35 (d, 1H, J = 6.3), 
3.22 (dd, 1H, J = 13.4, 10.1), 3.17 (s, 3H), 3.07 (s, 3H), 2.53 (dd, 1H, J = 13.4, 5.5), 
2.40 (m, 1H), 2.18 (m, 1H) 2.10 (m, 1H), 2.01 (m, 1H), 0.90 (m, 9H), 0.15 (s, 3H), 0.13 
(m, 3H). 13C NMR (75 MHz, CDCl3) δ 81.93, 80.54, 79.99, 72.95, 60.80, 44.42, 15.14, 
12.56, 7.82, 0.20, -1.84, -27.06, -29.22, -35.90, -36.81, -42.05, -51.34, -59.19, -79.57, -
79.66. 
(3’S,6’R)- N2-{N,N-Dimethylformamidino}-9-{5’-O-[4,4’-(dimethoxytriphenyl)methyl]-
3’-O-[(tert-butyl)-dimethylsilyl]-2’-deoxy-3’,5’-ethano-β-D-ribofuranosyl} guanine 46b 
To a solution of nucleoside 45b (70 mg, 0.15 mmol) in pyridine (0.7 ml) was added 
DMT-Cl (154 mg 0.45 mmol) in three portions and it was stirred for 24 h at r.t. The 
solution was then diluted with ethyl acetate, washed with sat. NaHCO3 and dried over 
MgS04. Purification by FC (5% methanol in DCM) yielded the nucleoside 46b (108 mg, 
0.14, mmol, 94%) as a white foam. Rf 0.66 (10% methanol in DCM), HR-MS (NSI
+, 
MeCN) for C42H52N6O6Si. Calc. 765.3790, found 765.3779 (M + H
+), 1H NMR (300 
MHz, CDCl3) δ 8.94 (br, 1H), 8.61 (s, 1H), 7.88 (m, 1H), 7.47 (m, 2H), 7.36 (m, 4H), 
7.30 (m, 1H), 7.20 (m, 1H), 6.83 (m, 4H), 6.19 (dd, 1H, J = 9.6, 5.1), 4.27 (m, 1H), 4.12 
(dd, 1H, J = 7.5, 3.9), 3.79 (s, 6H), 3.13 (s, 3H), 3.10 (s, 3H), 2.73 (dd, 1H, J = 13.0, 
9.6), 2.42 (dd, 1H, J = 13.0, 5.1), 1.98 (m, 1H), 1.68 (m, 1H), 1.60 (m, 2H), 0.83 (s, 
9H,), 0.04 (s, 3H), -0.04 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 158.86, 158.29, 157.96, 
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156.81, 150.17, 145.69, 136.96, 136.21, 130.28, 128.28, 128.22, 127.11, 113.55, 90.76, 
88.62, 87.44, 84.73, 75.66, 55.47, 46.96, 45.56, 41.51, 39.70, 35.37, 25.88, 18.02, -2.63. 
(3’S, 6’R)-N2-{N,N-Dimethylformamidino}-9-{6’-O-[4,4’-(dimethoxytriphenyl)methyl]- 
2’-deoxy-3’,5’-ethano-β-D-ribofuranosyl} guanine 47b Nucleoside 46b (74 mg, 0.1 
mmol) was dissolved in THF (2.2 ml) and TBAF (1 M in THF, 0.1 ml, 0.1 mmol) was 
added. The clear solution was stirred for 5 h at r.t. and then quenched by the addition of 
silica. Purification by FC (5% methanol in DCM) yielded 47b (44 mg, 70 %) as a white 
foam. Rf 0.4 (10% methanol in DCM), HR-MS (NSI
+, MeCN, 0.1% HFo) for 
C36H38N6O6. Calc. 651.2926, found 651.2925 (M + H
+) 1H NMR (400 MHz, MeOD) δ 
8.68 (s, 1H), 7.97 (s, 1H), 7.46 (m, 2H), 7.34 (m, 4H), 7.27 (m, 2H), 7.21 (m, 1H), 6.84 
(m, 4H), 6.24 (dd, 1H, J = 9.4, 5.4), 4.33 (m, 1H), 4.08 (dd, 1H, J = 7.4, 3.4), 3.78 (s, 
6H), 3.16 (s, 3H), 3.12 (s, 3H), 2.91 (dd, 1H, J = 13.1, 9.5), 2.49 (dd, 1H, J = 13.2, 5.4), 
1.95 (m, 1H), 1.82 (m, 1H), 1.67 (dd, 1H, J = 14.0, 6.1), 1.57 (m, 1H). 13C NMR (101 
MHz, MeOD) δ 160.25, 159.82, 159.17, 151.84, 147.10, 138.25, 138.09, 138.06, 
131.32, 129.33, 128.92, 127.86, 120.65, 114.27, 90.89, 88.62, 87.54, 85.98, 77.02, 
55.73, 47.44, 46.93, 41.52, 40.74, 35.33. 
(3’S,6’R)-N2-{N,N-Dimethylformamidino}-9-{3’-O-[(2-
cyanoethoxy)(diisopropylamino)phosphino]-6’-O- [4,4’-(dimethoxytriphenyl)methyl]-
3’-O-[(tert-butyl)-dimethylsilyl]-2’-deoxy-3’,5’-ethano-β-D-ribofuranosyl} guanine 48b 
To a solution of 47b (44 mg, 0.07 mmol) in MeCN (1 ml) was added Hünig’s base 
(0.06 ml, 0.34 mmol) and Cep-Cl (0.04 ml, 0.2 mmol). The mixture was stirred at r.t. 
for 1 h then diluted with ethyl acetate and washed with sat. NaHCO3. Purification by FC 
(3% methanol in DCM) yielded the desired phosphoramidite 48b (50 mg, 0.06 mmol, 
88%) as a white foam. Rf 0.7 (10% methanol in DCM), HR-MS (NSI
+, MeCN) for 
C45H55N8O7P. Calc. 851.4010, found 851.4009 (M + H
+), 1H NMR (400 MHz, CDCl3) 
δ 8.95 (br, 1H), 8.60 (m, 1H), 7.85 (m, 1H), 7.45 (m, 2H), 7.35 (m, 4H), 7.28 (m, 2H), 
7.21 (m, 1H), 6.83 (m, 4H), 6.22 (m, 1H), 4.32 (m, 2H), 3.79 (m, 6H), 3.77-3.54 (m, 
4H), 3.13 (s, 3H), 3.09 (m, 3H), 2.84 (m, 2H), 2.57 (t, 1H, J = 6.3), 2.51 (t, 1H, J = 6.3), 
2.09 (m, 1H), 1.86 (m, 2H), 1.60 (m, 1H), 1.15 (m, 9H), 1.09 (d, 3H, J = 6.8). 13C NMR 
(101 MHz, CDCl3) δ 158.80, 158.33, 158.00, 156.94, 156.88, 150.38, 150.30, 145.66, 
136.87, 136.83, 136.38, 130.30, 130.25, 128.24, 127.08, 120.90, 117.75, 113.53, 90.91, 
90.82, 90.76, 89.12, 87.55, 87.52, 84.33, 75.62, 75.51, 58.20, 58.02, 57.92, 55.46, 
44.92, 44.60, 43.59, 43.47, 41.50, 39.41, 35.36, 29.89, 24.75, 24.50, 20.53. 31P NMR 
(122 MHz, CDCl3) δ 141.88. 
RNase H activity: A 0.2 μM solution of the oligonucleotide S10 and of the 
corresponding DNA and RNA strands was solved in a buffer system containing 75 mM 
KCl, 50 mM Tris-HCl, 3mM MgCl2 and10 mM dithiothreitol and was then hybridized 
with 0.1 μM of the 32P labelled complementary RNA strand to give a total volume of 60 
μl. After heating to 80°C the solution was incubated for 15 min. at 37°C. 2.5 U of the 
enzyme were then added and the mixture was kept at 25°C. Aliquots were taken at 5, 
45, 120 and 300 min. and were quenched by the addition of a loading buffer (100% 
formamid, bromphenol blue and xylencyanol). The samples were stored at 4°C over 
night, analysed on a 20% denaturing polyacrylamide gel and the bands visualized by 
autoradiography. 
Serum stability: 202 μl of the sequence S10 and 108 μl of the corresponding DNA 
sequence (~30 μg each) were speed vac dried. The remains were taken up in 386 μl 
DMEM/F12 (Dulbecco’s Modified Eagle Medium), incubated at 37°C and 40 μl of FBS 
was added to give a total concentration of 10% serum. Aliquots of 84 μl were taken 
after 0, 0.5, 2, 6.5 and 21 h and quenched by the addition of 80 μl 9 M urea in 2x TBE 
buffer. To the solutions were then added 60 μl of H2O and they were precipitated in 25 
μl 3 M NaOAc and 1 ml cold ethanol. After 1 h at -80°C the tubes were centrifuged for 
1 h at 2 °C. The remains were taken up in 15 μl loading buffer (formamide/TBE 9:1) 
and separarated on a 20% polyacrylamide gel. In order to visualize the bands the gel 
was stained with stains-all.  
iso-bicyclo oligonucleotide synthesis: The chemical synthesis of oligonucleotides was 
performed on the 1.3μmol scale on a Pharmacia LKB Gene Assembler Special DNA-
synthesizer using standard phosphoramidite chemistry. The phosphoramidite building 
blocks of the natural nucleosides and the nucleosides bound to CPG-solid support were 
purchased from Glen Research. Universal solid support was purchased from Glen 
Research or CTGen. Natural oligonucleotides were purchased from Microsynth. 
Solvents and reagents used for the synthesis were prepared according to the 
manufacturer’s indications. 5-(ethylthio)-1H-tetrazole (ETT) was used as activator and 
dichloroacetic acid in dichloroethane was used for the detritylation step. The 
concentrations of the phosphoramidite solutions were 0.1 M. The coupling times for 
natural phosphoramidites were 1.5 min and for the modified phosphoramidite 9 min. 
The oligonucleotides S1-S4 were cleaved from the resin and deprotected in 33% NH3 
solution at 55°C overnight. Also the fully modified sequences S6, S7, S10, S11 were 
cleaved and deprotected in 33% NH3 but at 70°C overnight. After evaporation the crude 
samples were filtered, taken up in water and purified by reversed phase (Source 15 RPC 
ST 100/4.6 Polystyrene-15 column from Pharmacia Biotech) or DEAE-HPLC 
(DNAPac-200 4 x 250 mm column with pre-column both from Dionex). All samples 
were then desalted over a Sep-Pak® C-18 cartridge (Waters) according to the 
manufacturer’s protocol. The integrity of all oligonucleotides was confirmed by ESI-
MS spectrometry. Concentrations of the oligonucleotide solutions were determined by 
UV absorption at 260 nm. The extinction coefficients ε of the oligonucleotides were 
supposed to be identical to natural oligonucleotides and were calculated using the 
oligocalculator (www.ambion.com). 
UV/Vis Spectroscopy: Thermal denaturation experiments were measured on a Cary 100 
Bio, UV-Visible Spectrophotometer. The samples were measured at 260 nm and the 
heating rate was set to 0.5°C/min. The first derivatives of the curves were calculated 
with the Origin Pro 8 program. To avoid evaporation of the solution, a layer of 
dimethylpolysiloxane was added over the samples within the cell. The OD values of the 
oligonucleotides were measured with a NanoDrop ND-1000 Spectrophotometer at 260 
nm. 
Circular dichroism spectroscopy (CD): Circular dichroism spectra were recorded on a 
Jasco J-715 spectropolarimeter equipped with a Jasco PFO-350S temperature 
controller. The temperature was measured from the heating block. The graphs were 
subsequently smoothed with a noise filter. The phosphate buffer was used as blank. 
Spectra are given in mdeg from 210 to 320 nm. 
Molecular modeling: Molecular modeling were carried out with the Amber force field 
as incorporated in the software package HyperChem™ Release 8.0.4 for Windows of 
Hypercube, Inc. Only original Amber parameters were used and no explicit water or 
counterions were included. 
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